O potencial imunossupressor de extrato de membrana amniótica humana by Duque, Marta
Universidade de Aveiro 
2015 
Departamento de Química 
  
MARTA DUQUE O POTENCIAL IMUNOSSUPRESSOR DE 
EXTRATO DE MEMBRANA AMNIÓTICA 
HUMANA 
 
THE IMMUNOSUPPRESSIVE POTENTIAL OF 
HUMAN AMNIOTIC MEMBRANE EXTRACT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Universidade de Aveiro 
2015 
Departamento de Química 
  
MARTA DUQUE O POTENCIAL IMUNOSSUPRESSOR DE 
EXTRATO DE MEMBRANA AMNIÓTICA 
HUMANA 
 
THE IMMUNOSUPPRESSIVE POTENTIAL OF 
HUMAN AMNIOTIC MEMBRANE EXTRACT 
 
Dissertação apresentada à Universidade de Aveiro para 
cumprimento dos requisitos necessários à obtenção do grau de 
Mestre em Bioquímica, Ramo Bioquímica Clínica, realizada 
sob a orientação científica do Doutor Artur Augusto Paiva, 
Técnico Superior de Saúde e Assessor no Instituto Português 
do Sangue e Transplantação de Coimbra, e Doutora Maria do 
Rosário Gonçalves dos Reis Domingues, Professora Auxiliar 
com Agregação do Departamento de Química da Universidade 
de Aveiro. 
  
Apoio financeiro da Fundação para a Ciência e a Tecnologia (FCT, Portugal), da União 
Europeia, QREN, no âmbito do Programa Operacional Temático Fatores de 
Competitividade (COMPETE), à unidade de investigação QOPNA (projecto PEst-
C/QUI/UI0062/2013; FCOMP-01-0124-FEDER-037296). 
 
Universidade de Aveiro                                                                                                    2015 
Marta Duque i 
O JÚRI 
presidente 
Prof. Doutor Pedro Miguel Dimas Neves Domingues 
Professor Auxiliar com Agregação do Departamento de Química da 
Universidade de Aveiro 
  
 Prof. Doutor Artur Augusto Paiva  
Investigador do Instituto Português do Sangue e da Transplantação de 
Coimbra e professor adjunto a tempo parcial do departamento de 
Ciências Biomédicas Laboratoriais da Escola Superior de Tecnologia da 
Saúde de Coimbra  
  
 Prof. Doutora Maria Teresa Teixeira Cruz Rosete  
Professora auxiliar da Faculdade de Farmácia da Universidade de 
Coimbra 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Universidade de Aveiro                                                                                                    2015 
Marta Duque ii 
AGRADECIMENTOS Ao meu orientador, o Dr. Artur Paiva, pela incrível 
oportunidade, pela orientação científica, essencial à 
concretização deste projeto, e por todo o seu apoio. 
À minha co-orientadora, Dra. Rosário Domingues, pela sua 
infinita disponibilidade, atenção e encorajamento.  
A toda a equipa da Citometria de Fluxo do Instituto 
Português do Sangue de Coimbra, em especial à Maria 
Jesus Inácio e Isabel Silva pela sua paciência e 
indispensável auxílio.  
Á equipa da Faculdade de Medicina da Universidade de 
Coimbra; Ana Mamede, Mafalda Laranjo, Maria João 
Carvalho, Ana Abrantes e Maria Filomena Botelho pela 
colaboração neste trabalho. 
À minha família, juntamente com as minhas desculpas pelas 
minhas continuadas ausências. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Universidade de Aveiro                                                                                                    2015 
Marta Duque iii 
Palavras-
chave 
células mesenquimais do estroma, citocina pro-inflamatória, 
imunossupressão, linfócitos T, membrana amniótica 
 
Resumo Tanto as células mesenquimais do estroma (MSCs) como a membrana 
amniótica humana (hAM) possuem capacidade imunoreguladora, levando a 
que vários estudos se debrucem sobre a sua aplicação na prevenção e 
tratamento de doenças imunológicas, e especialmente sobre a sua capacidade 
de modular células T. No entanto, há pouca informação acerca dos efeitos 
concretos sobre diferentes fases de ativação e diferenciação de células T. O 
principal objetivo deste estudo foi determinar se um extrato de hAM 
(hAME) exerce efeito diferencial sobre diferentes subpopulações de células 
T (células T CD4
+
 e CD8
+
 naïve, memória central, memória efetoras e 
efetoras). Para esse efeito, células mononucleares do sangue periférico 
(PBMC) foram cultivadas na presença ou ausência de hAME e estimuladas 
com acetato miristato de forbol (PMA) mais ionomicina. A proliferação 
celular foi avaliada por um ensaio de incorporação de timidina e as 
percentagens de linfócitos T produtores de citocinas pró-inflamatórias foram 
determinadas por citometria de fluxo. O fenótipo de células derivadas de 
hAM foi também determinado por citometria de fluxo. Foi ainda estudada a 
expressão de mRNA em células T CD4
+
 e CD8
+
, células T reguladoras 
(Treg) e células T γδ purificadas. As células derivadas de hAM continham 
células epiteliais e MSCs. O extrato exibiu um efeito anti-proliferativo e 
reduziu a frequência de células produtoras de fator de necrose tumoral alfa 
(TNFα), interferão gama (IFNγ), e interleucina-2 (IL-2) em todas as 
subpopulações de células T estudadas, assim como a frequência de células T 
produtoras de IL-17 e IL-9. O padrão de inibição variou entre células T 
CD4
+
 e CD8
+
, entre cada subpopulação celular, e dependendo da citocina em 
estudo. O hAME provovou também diminuição da expressão de mRNA de 
granzima B, perforina e recetor de ativação NKG2D em células T CD8
+
e 
células T γδ, assim como o aumento de expressão de Foxp3 e IL-10 em 
células T CD4
+
, e aumento de expressão IL-10 em células Treg. O hAME 
regula diferencialmente diferentes subpopulações de células T e, portanto, o 
efeito do hAME sobre respostas de células T será dependente das 
subpopulações de células T envolvidas, ainda assim, hAME tem uma ação 
global anti-inflamatória. 
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Abstract Both mesenchymal stromal cells (MSCs) and human amniotic membrane 
(hAM) possess immunoregulatory potential, driving several studies to focus 
on their application in the prevention and treatment of immunological 
disorders, and especially on their ability to modulate T cell responses. 
However there is little information regarding the concrete effects over 
different activation and differentiation stages of T cells. The main objective 
of this study was to determine whether or not a hAM extract (hAME) had a 
differential effect over different T cell subpopulations (CD4
+
 and CD8
+
 T 
naïve, central memory, effector memory and effector cells). Thus, peripheral 
blood mononuclear cells (PBMC) were cultured in the presence or absence 
of hAME and stimulated with phorbol myristate acetate (PMA) plus 
ionomycin. Cell proliferation was evaluated through a thymidine 
incorporation assay and the percentages of pro-inflammatory cytokine 
producing T cells were determined by flow cytometry. The phenotype of 
hAM-derived cells was also assessed by flow cytometry. Plus, the mRNA 
expression of selected genes was evaluated in purified CD4
+
 and CD8
+
 T 
cells, regulatory T cells (Treg) and γδ T cells. The hAM-derived cells 
contained hAM epithelial cells and MSCs. The extract displayed an anti-
proliferative effect and reduced the frequency of tumor necrosis factor-alpha 
(TNFα), interferon gamma (IFNγ), and interleukin-2 (IL-2) producing cells, 
within all T cell subsets. The hAME also diminished the frequency of IL-17 
and IL-9 producing T cells. The pattern of inhibition varied between CD4
+
 
and CD8
+
 T cells, between T cell subsets, and depending on the cytokine 
under study. The hAME also produced a decrease in mRNA expression of 
granzime B, perforin and activating receptor NKG2D by CD8
+
 T cells, γδ T 
cells as well as an upregulation of Foxp3 and IL-10 gene expression in CD4
+
 
T cells and an upregulation of IL-10 mRNA expression in Treg cells. These 
results show that the hAME differentially regulates different T cell subsets 
and therefore the effect of the hAME over T cells responses will depend on 
the T cell subpopulations involved. Still, the hAME has an overall anti-
inflammatory action. 
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IMAGE INDEX 
 
Figure 1. Cross section of the human amnion (above) and chorion (below), showing an 
epithelial layer, a compact layer, a fibroblast layer, an intermediate (spongy) 
layer, a reticular layer and the trophoblast. Original magnification ×90; from 
Bourne 1962. 
Figure 2. Schematic diagram illustrating the layers that compose the human amnion and 
chorion. The amniotic membrane is composed of a single layer of epithelial 
cells, a basement membrane, a compact layer and a fibroblast layer. The 
amnion is separated from the chorion by an intermediate (spongy) layer. The 
chorion consists of a reticular layer, basement membrane and multi-layered 
trophoblast cells. The fibroblast (amnion) and reticular layers (chorion) contain 
mesenchymal cells (M). Adapted from Bourne 1962. 
Figure 3. Mesenchymal stromal cell differentiation markers. Theoretical hierarchy of 
mesenchymal stem cell differentiation. Myogenic differentiation ( ) has 
been demonstrated in vitro but not in vivo. From R&D Systems Tools for Cell 
Biology Research
TM
  2014. 
Figure 4. Proposed model for biological functions and mechanisms of action of MSCs in 
response to tissue damage and/or infection. Transdifferentiation may occur in 
vivo but is not the main mechanism underlying MSC-mediated therapeutic 
effects, instead, the endocrine/paracrine secretion of regenerative and 
immunossupressive factors, independently of the anatomical location, 
promotes tissue repair and protects the host against inflammation damage. No 
one mechanism of immunomodulation is prevalent, instead, MSC possess a 
redundant panel of numerous pathways, some of which act in synergy. Solid        
(  ) and dashed lines (  ) represent direct and indirect effects, 
respectively, the arrows (  ) represent stimulation and the end-circles (  ) 
inhibition. 
Figure 5.  A shematic representation of the functional plasticity of MSCs. During the first 
stages of the response to infection/injury (or in cases of chronic inflammation), 
the low levels of inflammation (insufficient inflammatory cytokines) lead 
MSCs to display a pro-inflammatory behavior (MSC1) that increases the 
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activity of immune effcetor cells, stimulating the removal of the infection (or 
worsening the disease state in case of chronic inflammation). Vigorous 
inflammation, on the othe hand, licenses MSCs to display an anti-inflammatory 
and regenerative behavior (MSC2) to prevent tissue damage and maintain the 
homeostasis. The arrows (  ) and end-circles (  ) represent stimulation 
and inhibition, respectively. 
Figure 6. Basic scheme of the methodology adopted for the evaluation of the 
immunosuppressive potential of hAME and hAM-derived cells. 
Figure 7.  Phenotypic characterization of hAM-derived cells. Left panel: Bivariate dot 
plot histogram illustrating the hAM-derived cells, following culture, displaying 
two distinct cell populations; A and B. Right panel: Phenotypic 
characterization of the two cell populations identified in hAM-derived cell 
cultures as the expression level of several phenotypic markers, measured as the 
mean fluorescence intensity (MFI) (mean ± SD). Results were obtained with 
four hAM samples. Statistically significant differences were considered when 
p<0.05 for the Mann-Whitney Test: * for the groups indicated in the figure. 
Figure 8. Thymidine incorporation assay. Results represent PBMC proliferation, 
measured as [H
3
]-thymidine incorporation (mean ± SD) without mitogen 
stimulation or following PBMC activation by mitogenic stimuli. Results were 
obtained for three PBMC samples. Statistically significant differences were 
considered when p<0.05 for the Wilcoxon paired-sample test: * for the groups 
indicated in the figure. 
Figure 9. Effect of different doses of hAME over the frequency of TNFα-expressing 
CD4
+
 and CD8
+
 T cells. (A-B) Percentage of TNFα-producing CD4+ (A) and 
CD8
+
 T cells (B) (mean ± SD) among four different subsets (naïve, central 
memory, effector memory and effector) following PBMC stimulation in the 
absence (PBMC + PMA + Ionomycin) or presence of hAME in the culture 
medium (PBMC + 50μL hAME + PMA + Ionomycin, PBMC + 100μL hAME 
+ PMA + Ionomycin, PBMC + 200μL hAME + PMA + Ionomycin). (C-D) 
Percent inhibition (mean ± SD) induced by hAME on the frequency of TNFα 
producing CD4
+
 (C) and CD8
+
 T cells (D). Results were obtained for three 
PBMC samples. Statistically significant differences were considered when 
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p<0.05 for the Wilcoxon paired-sample test: * versus PBMC + PMA + 
Ionomycin; ** for the groups indicated in the figure. 
Figure 10. Effect of hAME over TNFα expressing CD4
+
 and CD8
+
 T cells. (A-B) 
Percentage of TNFα producing CD4+ (A) and CD8+ T cells (B) (mean ± SD), 
distributed among the naïve, central memory, effector memory and effector 
subsets, following PBMC stimulation in the absence (PBMC + PMA + 
Ionomycin) or presence of hAME in the culture medium (PBMC + 200μL 
hAME + PMA + Ionomycin). (C-D) Amount of TNFα expressed per CD4+ (C) 
and CD8
+
 T cell (D), measured as the MFI (mean ± SD). (E-F) Percent 
inhibition (mean ± SD) induced by hAME on the frequency of TNFα 
producing CD4
+
 and CD8
+
 T cells (E) and amount of TNFα expressed per cell 
(F). Results were obtained for eight PBMC samples. Statistically significant 
differences were considered when p<0.05 for the Wilcoxon paired-sample test: 
* versus PBMC + PMA + Ionomycin; ** for the groups indicated in the figure. 
Figure 11. Effect of hAME over IFNγ expressing CD4
+
 and CD8
+
 T cells. (A-B) 
Percentage of IFNγ producing CD4+ (A) and CD8+ T cells (B) (mean ± SD), 
distributed among the naïve, central memory, effector memory and effector 
subsets, following PBMC stimulation in the absence (PBMC + PMA + 
Ionomycin) or presence of hAME in the culture medium (PBMC + 200μL 
hAME + PMA + Ionomycin). (C-D) Amount of IFNγ expressed per CD4+ (C) 
and CD8
+
 T cell (D), measured as the MFI (mean ± SD). (E-F) Percent 
inhibition (mean ± SD) induced by hAME on the frequency of IFNγ producing 
CD4
+
 and CD8
+
 T cells (E) and amount of IFNγ expressed per cell (F). Results 
were obtained for eight PBMC samples. Statistically significant differences 
were considered when p<0.05 for the Wilcoxon paired-sample test: * versus 
PBMC + PMA + Ionomycin; ** for the groups indicated in the figure. 
Figure 12. Effect of hAME over IL-2 expressing CD4
+
 and CD8
+
 T cells. (A-B) 
Percentage of IL-2 producing CD4
+
 (A) and CD8
+
 T cells (B) (mean ± SD), 
distributed among the naïve, central memory, effector memory and effector 
subsets, following PBMC stimulation in the absence (PBMC + PMA + 
Ionomycin) or presence of hAME in the culture medium (PBMC + 200μL 
hAME + PMA + Ionomycin). (C-D) Amount of IL-2 expressed per CD4
+
 (C) 
and CD8
+
 T cell (D), measured as the MFI (mean ± SD). (E-F) Percent 
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inhibition (mean ± SD) induced by hAME on the frequency of IL-2 producing 
CD4
+
 and CD8
+
 T cells (E) and amount of IL-2 expressed per cell (F). Results 
were obtained for eight PBMC samples. Statistically significant differences 
were considered when p<0.05 for the Wilcoxon paired-sample test: * versus 
PBMC + PMA + Ionomycin; ** for the groups indicated in the figure. 
Figure 13. Effect of hAME over IL-9
+
 and IL-9
+
IL-2
+
 T cells. (A) Percentage of IL-9 
producing cells (mean ± SD), within total CD4
+
 and CD8
+
 T cells, following 
PBMC stimulation in the absence (PBMC + PMA + Ionomycin) or presence of 
hAME in the culture medium (PBMC + 200μL Hame + PMA + Ionomycin). 
(B) Percentage of IL-9 producing T cells that simultaneously express IL-2 
(mean ± SD). (C-D) Amount of protein expressed per cell among IL-9
+
 (C) and 
IL-9
+
IL-2
+
 T cells (D) (MFI, mean ± SD). (E-F) Percent inhibition (mean ± 
SD) induced by hAME over the frequency of IL-9
+
 and IL-9
+
IL-2
+
 T cells (E) 
and amount of cytokine expressed per cell (F). Results were obtained for eight 
PBMC samples. Statistically significant differences were considered when 
p<0.05 for the Wilcoxon paired-sample test: * versus PBMC + PMA + 
Ionomycin; ** for the groups indicated in the figure. 
Figure 14. Effect of hAME over IL-17
+
, IL-17
+TNFα+, IL-17+IFNγ+ and IL-17+IL-2+ T 
cells. (A) Percentage of IL-17 producing cells (mean ± SD), within total CD4
+
 
and CD8
+
 T cells following PBMC stimulation the absence (PBMC + PMA + 
Ionomycin) or presence of hAME in the culture medium (PBMC + 200μL 
hAME + PMA + Ionomycin). (B-D) Percentage of IL-17 producing CD4
+
 and 
CD8
+
 T cells that simultaneously express TNFα (B), IFNγ (C) or IL-2 (D). (E-
H) Amount of protein expressed per cell among IL-17
+
 (E), IL-17
+TNFα+ (F), 
IL-17
+IFNγ+ (G) and IL-17+IL-2+ T cells (H) (MFI, mean ± SD). (I-J) Percent 
inhibition (mean ± SD) induced by hAME on the frequency of IL-17
+
, IL-
17
+TNFα+, IL-17+IFNγ+ and IL-17+IL-2+ T cells (I) and amount of cytokine 
expressed per cell (J).  Results were obtained for eight PBMC samples. 
Statistically significant differences were considered when p<0.05 for the 
Wilcoxon paired-sample test: * versus PBMC + PMA + Ionomycin; ** for the 
groups indicated in the figure. 
Figure 15.  Effect of hAM-derived cells over the frequency of IL-2 expressing T cells. 
Percentage of IL-2 producing cells among different CD4
+
 (A) and CD8
+
 T cell 
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(B) subsets (naïve, central memory, effector memory and effector) (mean ± 
SD) following PBMC stimulation in the absence (PBMC + PMA + Ionomycin) 
or presence of hAM-derived cells, in a proportion of PBMC-to-hAM-derived 
cells of either 10:1 (PBMC + 10:1 hAM cells + PMA + Ionomycin) or 2:1 
(PBMC + 2:1 hAM cells + PMA + Ionomycin), in the culture medium. Results 
were obtained for two PBMC samples and two replicates. Statistically 
significant differences were considered when p<0.05 for the Wilcoxon paired-
sample test: * versus PBMC + PMA + Ionomycin. 
Figure 16.  mRNA expression in purified CD4
+
, CD8
+, γδ T and Treg cells. Semi-
quantitative analysis of mRNA expression in FACS-purified T cells from two 
separate culture conditions: PBMC stimulated in the absence (PBMC + PMA + 
Ion; blue bars) or presence of hAME (PBMC + 200μL hAME + PMA + Ion; 
orange bars). Results were obtained for five PBMC samples. Statistically 
significant differences were considered when p<0.05 for the Wilcoxon paired-
sample test: * for the groups indicated in the figure. 
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1. INTRODUCTION 
 
1.1. INNATE AND ADAPTIVE IMMUNITY 
 
Immune responses are a set of complex and interconnected mechanisms that provide the 
organism protection against disease. These mechanisms are carried out by a vast collection 
of cells and molecules, which constitute the immune system. 
The innate immune responses are the first protective part of the immune system; they 
pose a barrier to infection and eliminate infecting microbes through universal mechanisms. 
The adaptive immune responses do not develop immediately, but represent a specific 
response to the antigen. These responses can also be elicited against life-saving organ 
transplants resulting in graft rejection, additionally, because the immense variety of 
receptors of the adaptive immunity is generated at random, the body can sometimes 
respond to harmless materials such as allergens (leading to allergies) and self-antigens 
(resulting in autoimmunity) (Abbas & Lichtman 2011).  
The innate immunity includes the external defenses, for example, the skin and mucous 
membranes, which form a barrier to the entry of infectious microbes and secrete natural 
antimicrobial substances. Other agents of innate immunity include lymphocytes, 
phagocytes and auxiliary plasma proteins (including the complement system and acute 
phase proteins) (Abbas & Lichtman 2011, Chapel et al. 2014, Playfair & Chain 2013). 
Antigen recognition by the innate immune system results in the activation of a set of 
basic functions with the purpose of removing the microbe from the host and releasing 
important inflammatory mediators (cytokines), to activate other immune cells, and 
chemoattractant cytokines (chemokines) that recruit immune cells to the site of 
inflammation. Neutrophils, macrophages and other phagocytes ingest and destroy microbes 
(cell-mediated immunity) while the products of complement activation coat the microbes 
(opsonization) to facilitate phagocytosis. Innate immune responses have also a crucial role 
in the initiation and enhancement of adaptive immune responses (Abbas & Lichtman 2011, 
Playfair & Chain 2013). 
Adaptive immune responses are produced exclusively by the activities and products of 
lymphocytes. They develop more slowly partially because activation only occurs if the 
antigen can reach a lymphoid organ, where the lymphocyte populations reside. However 
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the adaptive immunity possesses many unique features that make it very effective, namely: 
i) the existence of receptors for virtually every antigen; ii) specificity for each particular 
antigen; iii) creation of specific memory; iv) adaptation through the increased efficacy and 
specialization of the response; v) clonal expansion to generate large numbers of 
lymphocytes directed against the antigen and vi) tight regulation and contraction that 
maintain homeostasis, allowing responses against ‘new’ antigens, and avoid autoimmunity 
(Abbas & Lichtman 2011). 
 
1.1.1. Lymphocytes 
The only host cells that express antigen-specific receptors are lymphocytes, a group of 
cells homogeneous in morphology but with great diversity in lineage, functions and 
phenotype. They derive from cell precursors in the bone marrow and mature in generative 
lymphoid organs; B cells mature within the bone marrow and T cells mature in the thymus. 
The resulting mature cells, in turn, reside in peripheral blood organs. Natural killer (NK) 
cells are lymphocytes which are components of the innate immune system. NK cells can 
directly kill infected host, but they do not possess the clonally distributed receptors typical 
of T and B cells (Abbas & Lichtman 2011, Chapel et al. 2014, Playfair & Chain 2013). 
The naïve lymphocytes, which have not yet encountered antigen, can recognize the 
antigen but cannot perform the actions to combat infection; instead, recognition drives 
clonal expansion and differentiation into memory and effector cells. B cells can 
differentiate into the effector plasma cells that produce large amounts of antibodies, while 
T lymphocytes generate many different effector phenotypes. The activated cells enter the 
blood and lymphatic fluid and can enter and leave tissues as needed (Abbas & Lichtman 
2011, Playfair & Chain 2013). 
B and T cells are morphologically similar but only T lymphocytes express the cluster of 
differentiation 3 (CD3); a T cell co-receptor. CD3 is present at the surface of all mature T 
cells (CD3
+
). The main subsets of T lymphocytes are the T cells that express CD4 (CD4
+
) 
and T cells that express CD8 (CD8
+
). CD4 and CD8 are co-receptors involved in the 
recognition of class II and class I major histocompatibility complex (MHC) molecules, 
respectively. In general, CD4
+
 T helper cells (Th) promote antibody production by B cells 
and enhance the activities of phagocytes. CD4
+
 or CD8
+
 regulatory T cells (Treg) have a 
suppressive function over the immune response and CD8
+
 T cytotoxic, or cytolytic, 
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lymphocytes (Tc) directly destroy infected cells to eliminate the microbes that are out of 
reach to antibodies (Abbas & Lichtman 2011). Antibodies opsonize and neutralize 
extracellular microbes. They are exclusively produced by B lymphocytes and especially by 
their differentiated form of plasma cells. Differentiation occurs when B cells recognize the 
antigen, soluble or at the surface of the microbe, through their surface receptors, which are 
membrane-bound antibodies. B cell receptors can recognize several types of antigenic 
substances; therefore antibody-mediated (humoral) responses can be elicited against a wide 
variety of antigens. In contrast, T cell receptors (TCRs) recognize only antigenic proteins, 
or protein fragments, presented by MHC molecules at the surface of antigen presenting 
cells (APCs), thus T cell responses can only be elicited against protein antigens of 
microbes.  The resulting response depends on the type of T cell and the class of MHC (the 
human MHC has the designation of human leukocyte antigen, HLA).  
All nucleated cells express MHC class I molecules which are recognized by the CD8
+
 T 
cells and NK cells, protecting the cell from destruction by inducing apoptosis in Tc cells 
and inhibiting NK cell activation. The absence of MHC class I molecules or the presence 
of foreign MHC class I leads to Tc and/or NK mediated cell death (Abbas & Lichtman 
2011, Playfair & Chain 2013), a process involved in alloreactive recognition and rejection 
of transplants (Li & Raghavan 2012).  
MHC class II molecules are typically expressed at the surface of APCs, such as dendritic 
cells (DCs), B lymphocytes and macrophages. The main function of MHC class II 
molecules is to present antigenic peptides to CD4
+
 T cells; the recognition of the MHC 
class II-antigen complex requires CD4 receptors as well as the T cell receptor (TCR) and 
triggers the activation of the CD4
+
 naïve T cell (Travers et al. 2001). Non-protein antigens 
captured by APCs cannot be recognized by T cells, but they can activate B lymphocytes 
(Abbas & Lichtman 2011, Chapel et al. 2014, Playfair & Chain 2013). 
T cells are unable to recognize the antigen without the previous processing by APCs and 
full activation also requires secretion of cytokines by the APC along with the interaction 
between a CD28 molecule at the T cell surface and a co-stimulatory molecule (CD80 or 
CD86) expressed by the APC.  
Effector lymphocytes are short-lived cells whose survival, proliferation and function is 
dependent on stimulation by the antigen, thus, after elimination of the infection, effector 
cells rapidly decrease in numbers, as the lack of stimuli leads to their death by apoptosis, 
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and the immune system returns to the resting state. However, memory cells (memory B 
cells and memory CD4
+
 or CD8
+
 T cells), also originated from lymphocyte activation, can 
last for years. Memory cells exist in higher numbers than the population of naïve cells 
specific for the same antigen and, in the case of re-exposure to the antigen, memory 
lymphocytes respond more rapidly and efficiently than the naïve cells (Abbas & Lichtman 
2011). 
 
1.1.1.1. T Lymphocyte subsets 
Upon activation, naïve CD4
+
 T cells can differentiate into several different subsets of 
effector CD4
+
 T cells (Th cells), which act mainly through the release of cytokines. 
Distinct Th subsets exert different effector functions and can be distinguished according to 
their cytokine-secreting profiles; the most well known are Th type 1 (Th1), type 2 (Th2) 
and type 17 (Th17) (Table 1). The precursor naïve CD4
+
 T cells are often considered to 
represent the type 0 (Th0) subset, characterized by the release of a vast panel of cytokines, 
and having an effect somewhere in between those of Th1 and Th2 (Abbas & Lichtman 
2011). 
 
Table 1. Characteristics of the main subsets of effector (and regulatory) T lymphocytes. 
 CD4
+
 T effector cells (T helper cells) 
 Key transcription 
factors 
Cytokines Main functions 
T
h
1
 
T-bet 
STAT1 
STAT4 
IL-2 
IFNγ 
TNFα/β 
Promotion of Tc and NK cell development 
Macrophage and NK cell activation 
Increase of IgG production 
Stimulation of antigen presentation 
T
h
2
 
GATA3 
STAT6 
IL-4, 5, 6, 9, 
10, 13 
 
Mast cell and eosinophil activation 
Increase of IgE production 
Increase of extracellular matrix production by 
macrophages 
T
h
1
7
 RORγt 
STAT3 
IL-17, 21, 22  
 
Neutrophilic, monocytic inflammation 
Stimulation of cytokine/chemokine secretion by 
non-immune cells 
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 CD8
+
 T effector cells (cytotoxic T cells) 
T
c1
  
 
 
Eomes 
T-bet 
IFNγ 
TNFα 
 
 
 
Destruction of infected cells by release of 
proteins that form pores in the membrane of the 
target cells and  induce DNA fragmentation  T
c2
 IL-4, 5, 10, 
13 
T
c1
7
 IL-17 
 CD4
+
 and CD8
+
 regulatory T cells 
T
re
g
 
FOXP3 
STAT5 
IL-10 
TGFβ 
Inhibition of cytokine production 
Inhibition of APCs, Tc cell, NK cell and 
monocyte activities 
Suppression of T cell activation 
Eomes, Eomesodermin; GATA3, GATA binding protein 3; IFNγ, Interferon gamma; IL, Interleukin; T-bet, 
T-box transcription factor TBX21; Th, T helper cell; Tc, cytotoxic T lymphocyte; RORγ, RAR-related 
orphan receptor gamma; STAT, Signal transducer and activator of transcription; TNFα, Tumor necrosis 
factor alpha; Treg, regulatory T cell 
 
Naïve CD8
+
 T cells, on the other hand, differeniate into the effector CD8
+
 cytotoxic T 
lymphocytes (Tc), highly effective in the direct destruction of damaged, infected, 
malignant or foreign cells; they typically secrete cytolytic proteins such as granulysin, 
granzime A/B and perforin.  
Due to the discovery of the ability of CD8
+
 T cells to produce a wider array of cytokines 
than initially thought, cytotoxic T cells are sometimes divided into distinct subsets 
according to the cytokines they release, in a manner similar to their Th counterparts: the 
more common type 1 subset (Tc1), like Th1 cells, is characterized by high production of 
IFNγ and TNFα; the type 2 (Tc2) arrises when CD8+ T cells undergo activation in the 
presence of IL-4, resulting in Tc cells that display the ability to secrete IL-4, IL-5, IL-10 
and IL-13 (cytokines usually associated with Th2 cells) and may have decreased 
production of IFNγ; and IL-17 producing CD8+ T cells are refered to as type 17 (Tc17) 
(Table 1) (Dobrzanski et al. 2004, Vukmanovic-Stejic et al. 2000). 
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Table 1.1. A summary of other (lesser known) T helper effector cell phenotypes. 
Additional CD4
+
 T effector phenotypes 
Th subset Cytokines Possible functions 
Th3 TGFβ 
IL-10 (low amounts) 
Oral tolerance towards nonpathogenic, non-self 
antigens 
Th9 IL-9 
IL-10 
Immunity against helminthes 
Involvement in tissue damaged associated with 
allergic inflammation, tumors and parasitosis  
Th22 IL-22 (preferentially) Protective role in the regulation of skin wound repair 
and healing 
Tfh IL-21 
IL-4 
Promotion of the development of antibody producing 
plasma cells and memory B cells 
Tr1 IL-10 
TGFβ (low amounts) 
Promotion and maintenance of immune tolerance 
IL, Interleukin; Th, T helper cell; Tfh, follicular B helper T cell; TGFβ, transforming growth factor β; Tr1, 
type 1 regulatory T cell 
 
Regulatory T cells are the most important functional pool of suppressive mechanisms of 
the immune system. Most Treg cells are CD4
+
, but there also exist CD8
+
 Treg cells. These 
cells are Foxp3
+
 and exhibit a high expression of CD25; the transcription factor Foxp3 is 
essential for the development of regulatory functions and CD25 is the alpha chain of the 
IL-2 receptor. Stimulation with IL-2 (a pro-inflammatory cytokine) is required for Treg 
cell survival and activity, which indicates that their suppressive effects are elicited and/or 
enhanced by inflammatory stimuli (Abbas & Lichtman 2011, Chapel et al. 2014, Playfair 
& Chain 2013).  
Despite of their pivotal role in immune regulation, there exist T cell subsets with 
regulatory phenotypes other than the naturally occurring CD4
+
CD25
+
 Treg cells (nTreg); 
for instance, the Th subsets include cells that can inhibit immune responses in a contact-
independent manner. These populations (induced CD4
+
 Treg cells or iTreg) are secondary 
suppressor cells, thought to originate directly from conventional CD4
+
 T cells in peripheral 
lymphoid tissues, under certain stimuli. The iTreg cells can be subdivided into two other 
types, according to the cytokine that cause their induction; Th3 and Tr1 (TGFβ and IL-10, 
Universidade de Aveiro                                                                                                    2015 
Marta Duque 7 
respectively). Following generation, each iTreg will preferentially produce the same 
cytokine that first cause their induction (Table 1.1). The nTreg and iTreg cells share similar 
phenotypic characteristics, such as Foxp3 expression, and have similar suppressive 
functions (Jonuleit & Schmit 2003, Lin et al. 2013). 
A portion of the activated lymphocytes differentiates into long-lived memory cells, 
forming a dynamic reservoir of ‘experienced’ T cells. The memory T cell pool can be 
subdivided into distinct subsets of memory-carrying T cells. The central memory T cells 
(TCM) are responsible for fast expansion in case of re-exposure and secrete IL-2. In 
response to antigen recognition TCM cells swiftly differentiate into effector memory T cells 
(TEM) that possess effector functions (Abbas & Lichtman 2011, Mackay 1999). 
There also exist populations of ‘unconventional’, more primitive, T cells; the gamma-
delta T cells (γδ T) and Natural Killer T cells (NKT), which are considered to have both 
innate and adaptive immune functions and can recognize non-protein antigens.  
The γδ T cells express a form of antigen receptor distinct from the ‘traditional’ TCR and 
normally do not express CD4 or CD8 (Abbas & Lichtman 2011, Delves et al. 2011). 
Activated γδ T cells can secrete IFNγ, IL-17 and IL-22 and have cytotoxic activity, 
through the relase of granzime A/B and perforin. Tγδ cells are also thought to possess 
immunosuppressive functions due to their ability to produce IL-10 (Abbas & Lichtman 
2011, Delves et al. 2011). 
NKT cells have morphologies and granule contents intermediate between T and NK cells 
and express surface markers usually associated with NK cells along with the expression of 
low levels of TCR. They can be either CD4
-
CD8
-
 or CD4
+
CD8
-
. Activated NKT cells 
stimulate many immune cells, including DCs, NK cells and B lymphocytes, through the 
secretion of IL-4 and IFNγ (Abbas & Lichtman 2011, Delves et al. 2011). 
 
 
 
 
 
 
 
 
Universidade de Aveiro                                                                                                    2015 
Marta Duque 8 
1.2. THE AMNIOTIC MEMBRANE 
 
The amnion, or amniotic membrane (AM), represents the innermost layer of the placenta; 
it is a thin (approximately 0.02 to 0.05 cm thick), resistant and highly flexible membrane of 
fetal origin composed of an epithelial layer, a basement membrane and an avascular 
stromal matrix. The former can be further subdivided into three layers; the compact layer, 
the fibroblast layer and the intermediate, or spongy, layer (Figure 1) (Bourne 1962, 
Mamede et al. 2012). 
 
 
Figure 1. Cross section of the human amnion (above) and chorion (below), showing an epithelial 
layer, a compact layer, a fibroblast layer, an intermediate (spongy) layer, a reticular layer and the 
trophoblast. Original magnification ×90; from Bourne 1962. 
 
The epithelium of the amniotic membrane consists of a single layer of cuboidal epithelial 
cells and is in direct contact with the amniotic fluid. The thin basement membrane, tightly 
adherent to the epithelium, is comprised of reticular connective tissue, as is the underlying 
compact layer, though the compact layer is much more thicke and dense. The adjacent 
fibroblast layer is the thickest of the five amniotic layers and, along with the epithelium, 
the only other which is not devoid of cells; it consists of loosely associated mesenchymal 
cells (fibroblasts) embedded in a sparse reticular network. The outer spongy layer joins 
together the amnion and the chorion and is composed of wavy bundles of reticular fibers 
immersed in mucin. While the chorion is firmly adherent to the underlying maternal 
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decidua, this intermediate, spongy, layer allows the amniotic membrane to slide smoothly 
upon the chorion. Additionally, when the amniotic membrane is harvested for medical use, 
the presence of this layer allows for the easy separation of the amnion from the chorion 
(Bourne 1962) (Figure 2). 
Following, approximately, the 18
th
 day of gestation, the fibroblast and spongy layers of 
the amnion (and occasionally the compact layer) also contain another cell type; the 
Hofbauer cells. Hofbauer cells are a tye of macrophages of mesenchymal origin that reach 
high numbers in the placenta, but become rarer as the pregnancy progresses, practically 
vanishing after the 4
th
 or 5
th
 month of gestation (Grigoriadis et al. 2013). 
 
 
Figure 2. Schematic diagram illustrating the layers that compose the human amnion and chorion. 
The amniotic membrane is composed of a single layer of epithelial cells, basement membrane, a 
compact layer and a fibroblast layer. The amnion is separated from the chorion by an intermediate 
(spongy) layer. The chorion consists of a reticular layer, basement membrane and multi-layered 
trophoblast cells. The fibroblast (amnion) and reticular layers (chorion) contain mesenchymal cells 
(M). Adapted from Bourne 1962. 
 
Because of its ability to decrease inflammation and fibrosis, promote wound healing and 
tissue repair, antimicrobial properties and negligible risk of allogeneic rejection, the AM as 
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long been used in tissue engineering and for therapeutic applications (Mamede et al. 2012, 
Davis 1910).  
The immune privilege of AM is due to an active immunosuppressive mechanism, which 
is thought to be involved in immune tolerance during pregnancy (Kubo et al. 2001). Many 
groups have demonstrated that the AM can inhibit T cell proliferation, Th1/Th2 cytokine 
production (Ueta et al. 2002), reduce infiltration and induce apoptosis of activated 
neutrophils (Park & Tseng 2000, Wang e al. 2001), monocytes, macrophages (Bauer et al. 
2007, Heiligenhaus et al. 2001) and lymphocytes (Bauer et al. 2009), and promote the 
polarization of M2 macrophages (Bauer et al. 2012, He et al. 2008), which have a 
stimulatory effect on Th2 and Treg cells (Sica & Mantovani 2012). These 
immunoregulatory effects are likely mediated by soluble factors, seeing as they can often 
be achieved through the use of soluble AM extract or AM culture medium (CM-AM) 
(Kubo et al. 2001, Ueta et al. 2002). 
Rossi et al. (2012) attempted to identify the factors present in CM-hAM responsible for 
the suppression of T cell proliferation and reported the involvement of prostaglandins 
(PGs), which are known to be released by hAM in culture. The group managed to 
reproduce the inhibitory effect using a mixture of PGs that mimicked those in the CM-
hAM, but to a lesser extent. Additionally, the suppression of PG production with 
cyclooxygenase (COX) inhibitors did not completely abrogate the inhibition of T cell 
proliferation demonstrating the involvement of other factors (Rossi et al. 2012). However, 
the study focused only on hAM without any type of stimuli and it is thought that the AM 
can respond to inflammatory stimuli by up-regulating anti-inflammatory factors, possibly 
enhancing the diversity of AM-derived immunosuppressive factors. Nonetheless, the study 
does prove that the inhibitory effects of hAM are constitutively expressed and that they 
rely, at least in part, on PGs. Likewise, it has been demonstrated that hAM produces and 
releases PGE2, an anti-inflammatory regulator of immune responses (Ueta et al. 2002). 
Hao et al. (2000), in a study with the same objective, reported the expression, by hAM, of 
several anti-inflammatory proteins, including the cytokine IL10, IL-1 receptor antagonist 
(IL1RA), all four tissue inhibitors of metalloproteinases (TIMPs) and thrombospondin-1 
(TSP-1) (Table 2).  
Among the TIMPs, TIMP3 was demonstrated to suppress Th1 cell responses, with a 
protective effect in autoimmune diseases (Murthy et al. 2012). Additionally, TIMP3 is 
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unique among the TIMP family because it can inhibit not only matrix metalloproteinases, 
but also the tumor necrosis factor α converting enzyme (TACE) that processes the 
membrane bound TNFα to its soluble, active form (Mohammed et al. 2003). TSP-1, in 
turn, is capable of regulating T cell responses through several mechanisms; firstly TSP-1 
can activate the secreted, inactive, form of TGFβ, bound to the latent TGF-beta binding 
protein (LTBP) and latency-associated peptide (LAP), by binding to LAP and making it 
unable to confer latency (Crawford et al. 1998). Secondly, the interaction between TSP-1 
and the surface T cell receptor CD47 induces the generation of CD4
+
Foxp3
+
 T cells from 
naïve and memory CD4
+
CD25
-
 T cells. Those cells were named T anergic-suppressor cells 
(Tas) by Gimbert at al. (2006) and were similar to the ‘normal’ Treg cells, but with a 
CD25 expression level similar to that of Th0 cells, and did not produce granzime B, which 
means that they did not possess cytolitic activity. Tas cells also produced very low 
amounts of cytokines (anergic) and were capable of suppressing T cell responses 
(suppressor) through a mechanism dependent on cell-cell contact, independent from TGFβ 
and IL-10, and that could not be inhibited by IL-1 or IL-6 (unlike nTreg cells) (Grimbert et 
al. 2006, Miller et al. 2013). Furthermore, the TSP-1/CD47 interaction inhibits hydrogen 
sulfide (H2S) signaling, a ‘potentiator’ of T cell activation, and, simultaneously, hampers 
the activation-dependent expression of the two enzymes needed for H2S biosynthesis; 
cystathionine β-synthase and cystathionine γ-lyase, further disenabling the autocrine 
actions of H2S in T cell activation (Avice et al. 2001). 
Transcriptomic and proteomic analysis of hAM further supported the hypothesis of the 
involvement of IL1RA, TIMPs and TGFβ (Hopkinson et al. 2006, Li et al. 2005), and 
revealed other proteins with immunoregulatory potential; namely, annexin A1 (AnxA1) 
(Hopkinson et al. 2006), Fas ligand (FasL) (Hao et al. 2000, Hopkinson et al. 2006), 
human leukocyte antigen G (HLA-G) (Kubo et al. 2001) and macrophage migration 
inhibitory factor (MIF) (Hopkinson et al. 2006) (Table 2). 
FasL expression is typical of for immune-privileged sites (Griffith et al. 1995) and has 
been shown to be involved in the apoptosis of maternal lymphocytes (Runic et al. 1996). 
FasL can induce T cell apoptosis via interaction with its receptor, Fas, expressed by 
activated T cells. However, it is thought that this regulation is differential between T cells 
subsets; with CD4
+
 Th1 cells being more sensitive to Fas-mediated apoptosis than CD4
+
 
Th2 or CD8
+
 T cells (Ramsdell et al. 1994, Suzuki & Fink 2000). 
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HLA-G is a non-classical HLA class I molecule, typical of fetal-derived placental cells, 
crucial for maintaining immune tolerance during pregnancy (Kubo et al. 2001). While 
hAM cells display little to no expression of the classical MHC class I molecules (HLA-A, 
B and C), making them a target for recognition and elimination by cytolytic cells, they do 
express HLA-G, which can interact with inhibitory receptors of NK cells and Tc cells 
(Hunt et al. 2005). In NK cells, this interaction, induces apoptosis while, in activated T 
cells, inhibits cell cycle progression (Bahri et al. 2006, Ketroussi et al. 2011). 
Additionally, HLA-G interaction with CD8 in Tc cells can induce apoptosis, independently 
of activation, through the up-regulation of FasL, which then acts as an autocrine inhibitor 
(Contini et al. 2003). However, this inhibition is thought to be mainly due to the hAM-
derived soluble isoforms of HLA-G, particularly HLA-G5, which is known to be involved 
in the protection of the fetus against aggression by the maternal immune system (Hunt et 
al. 2005), and not for the membrane bound HLA-G (Bahri et al. 2006, Hunt et al. 2005).  
Heavy chain-hyaluronic acid/pentraxin 3 complex (HC-HA/PTX3), isolated from extracts 
of hAM, has been demonstrated to induce apoptosis of pro-inflammatory neutrophils and 
macrophages, reduce macrophage influx to allograft sites, enhance the phagocytosis by 
macrophages, induce Treg cell expansion and inhibit CD4
+
 T cell activation, specially 
towards Th1 cells (He et al. 2009, He et al. 2014). 
 
Table 2. Summary of the main hAM-derived factors with immunological properties. 
Soluble factor Effects on immune cells 
AnxA1 Promotion of Th1 cell responses (activation dependent) (D’Aquisto et 
al. 2007, Gavins & Hickey 2012) 
HLA-G Induction of apoptosis in NK and Tc cells (Bahri et al. 2006, Contini et 
al. 2003, Ketroussi et al. 2011) 
Inhibition of T cell proliferation (Contini et al. 2003, Ketroussi et al. 
2011) 
HC-HA/PTX3 Induction of Treg cells; 
Inhibition of CD4
+
 T cell activation; 
Inhibition of Th1 cell responses; 
Apoptosis of pro-inflammatory macrophages and neutrophils; 
Decrease in macrophage infiltration; 
Stimulation of macrophage-mediated phagocytosis (He et al. 2014) 
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TIMP3 Suppression of Th1 cell responses (Murthy et al. 2012) 
Inhibition  of TACE activity (Mohammed et al. 2003) 
IL-10 Inhibition of T cell responses and Th17 differentiation (Hao et al. 2000) 
IL1RA Antagonizes the effects of the pro-inflammatory cytokine IL-1 (Hao et 
al. 2000) 
FasL Induction of apoptosis in activated T cells (Runic et al. 1996) 
MIF Promotion of Th1 cell responses (Kithcart et al. 2010, Larson & Horak 
2006) 
Stimulation of pro-inflammatory cytokine production (Bacher et al. 
1996, Kithcart et al. 2010, Larson & Horak 2006) 
Reduction of Treg cell population (Kithcart et al. 2010) 
Increase of PGE2 production (Kithcart et al. 2010, Leng et al. 2003) 
PGE2 Inhibition of T cell proliferation; 
Promotion of of Th2 cell responses (Woorlard et al. 2007) 
Inhibition of DC maturation and macrophage activity; 
Induction of Treg cells (Baratelli et al. 2005) 
Inhibition of Th1 cell responses (Kalinski 2012) 
Suppression of Tc, NK and Th1 cell activation (Bydlowski et al. 2009) 
TSP-1 TGFβ activation (Crawford et al. 1998) 
Inhibition of T cell activation (Avice et al. 2001) 
Induction of T anergic-suppressor cells (Grimbert et al. 2006) 
Anx1, Annexin A1; HLA-G, Human leukocyte antigen G;  HC-HA/PTX3, Heavy chain-hyaluronic 
acid/pentraxin 3 complex; TIMP3, Tissue inhibitor of metalloproteinases 3; IL-10, Interleukin 10; IL1RA, 
IL-1 receptor antagonist; FasL; Fas ligand; MIF, Macrophage migration inhibitory factor; PGE2, 
Prostaglandin E2; TSP-1, Thrombospondin-1 
 
Contrary to the immunosuppressive effect of the other factors, hAM-derived AnxA1 and 
MIF seem to have pro-inflammatory actions. AnxA1 favors the generation of Th1 cells by 
binding to the receptor formyl peptide receptor-like-1 (FPRL-1). FPRL-1 usually exists at 
very low levels at the surface of T cells but, upon TCR activation, is quickly up-regulated 
and externalized, along with the increase of AnxA1 secretion (Gavins & Hickey 2012). 
When the FPRL-1/AnxA1 interaction occurs, along with the engagement of TCR, it drives 
the differentiation towards the Th1 phenotype (D’Aquisto et al. 2007, Gavins & Hickey 
2012). On the other hand, the FPRL-1/AnxA1 interaction is unable to activate T cells on its 
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own; therefore this regulatory mechanism may not have a significant effect on T cell 
responses within an environment that actively inhibits T cell activation. In addition, there 
have been reports of AnxA1 having a potential role in the suppression of adaptive immune 
responses in certain contexts (D’Aquisto et al. 2007), but the data is still controversial and 
demands further investigation. 
Similarly to AnxA1, MIF is also thought to stimulate Th1 responses (Larson & Horak 
2006), to promote the secretion of pro-inflammatory cytokines by T lymphocytes (Bacher 
et al. 1996, Larson & Horak 2006) and to reduce the population of Treg cells (Kithcart et 
al. 2010). MIF is bound by CD74 (HLA class II histocompatibility antigen gamma chain) 
in T cells (Larson & Horak 2006, Leng et al. 2003), stimulating the production of TNFα, 
IFNγ, IL-2, IL-1β, IL-6 and IL-8, and favoring the Th1 phenotype (Larson & Horak 2006, 
Kithcart et al. 2010). However, engagement of CD74 by MIF is also known to up-regulate 
COX-2 and strongly stimulate PGE2 production (Kithcart et al. 2010, Leng et al. 2003), 
which promotes the generation of CD4
+
 Treg cells (Baratelli et al. 2005), suppresses Tc, 
NK and Th1 cell activation and promotes the less aggressive Th2 phenotype (Kalinski 
2012). 
Several studies have focused on the clinical efficacy of hAM transplantation in the 
suppression of inflammation and promotion of wound healing and, in recent years, extracts 
or homogenates of hAM have been shown to exert the same effects as effectively as hAM 
transplantation (Guo et al. 2011, He et al. 2008, He et al. 2009, He et al. 2014). For 
instance, Guo et al. (2011) showed that treatment with an amnion homogenate (with a 
protein content of 3.6 mg/mL) was as successful as hAM transplantation in the repair of 
corneal damage, with clear reduction of ocular inflammation, further proving that the 
cellular factors responsible for the therapeutic effects of hAM are equally present in its 
extracts, potentially presenting a far simpler alternative to the use of hAM.  
hAM extract preparations have become commercially available, although by a very 
limited number of producers, in the form of a lyophilized powder, prompting investigators 
to focus their attention on its therapeutically applications, however, the subject is relatively 
recent and, so far, there have been scarce attempts to examine concrete effects over 
specific immune cell populations. 
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1.3. MESENCHYMAL STROMAL CELLS 
 
1.3.1. Nature and function of MSCs 
Mesenchymal stromal cells (MSC) are a rare, heterogeneous population of stromal, 
plastic adherent cells, morphologically similar to fibroblasts, with self-renewal capability 
and the ability to differentiate into several different lineages (Bydlowski et al. 2009, 
Pittenger et al. 1999). 
Although having been originally identified in the stroma of bone marrow (Friedenstein et 
al. 1968), which still constitutes their main source, MSCs can be isolated from virtually 
every post-natal tissue (Chong et al. 2012, Hoogduijn et al. 2007, In’t et al. 2003, Jo et al. 
2007, Patel et al. 2008, Vellasamy et al. 2012, Yang et al. 2013, Zuk et al. 2002). This 
wide distribution suggests that, all throughout the lifespan of each individual, MSCs might 
have a widespread role in tissue repair and regeneration (Cai et a. 2004). Because of this, 
MSCs are considered promising candidates for application in the treatment of several 
diseases, particularly since they can be activated and recruited to damage sites, where they 
promote tissue repair. Moreover, MSCs possess several features that further increase the 
interest in developing MSC-based therapies, namely; i) MSCs are not subjected to ethical 
issues; ii) they avoid allogeneic rejection; iii) there is very low risk of teratome formation 
(even if derived from a teratoma-forming human embryonic stem cell line [Gruenloh et al. 
2011]); iv) they can be isolated from practically any tissue, and v) are effortlessly 
expanded in vitro, from small samples to clinical levels that can be stored for long-periods 
without significant loss of multipotency (Madrigal et al. 2014). 
Identification and characterization of MSCs is complicated due to the lack of a unique 
marker (Dominici et al. 2006), still, all MSCs share numerous features and are usually 
defined by their expression profile based on a panel of several markers (Bydlowski et al. 
2009, Dominici et al. 2006, Qian et al. 2012) (Table 3).  
However, because the expression of surface markers is highly dependent on the cell 
source and the method of isolation and expansion, definitive identification also requires the 
assessment of their general biological characteristics, namely; fibroblast-like morphology, 
ability to adhere to plastic surfaces, self-renewal potential and differentiation into 
adipocytes, chrondocytes and osteoblasts (Bydlowski et al. 2009, Dominici et al. 2006). 
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Table 3. Positive and negative markers (proposed by the International Society for Cellular 
Therapy) for MSC identification. 
Positive Marker Function 
CD105 Endoglin; Part of the TGFβ receptor 
CD13 Aminopeptidase N; Inactivation of bioactive peptides 
CD44* Cell-cell interactions, cell adhesion and migration 
CD73 5’ Nucleotidase; Adenosine monophosphate conversion to adenosine 
CD90 Thy1; Cell-cell and cell-matrix interactions 
Negative Marker Excludes 
CD11b and CD14 Monocytes  and macrophages 
CD34 Hematopoietic and endothelial cells 
CD45 Leukocytes 
CD79α and CD19α B cells 
HLA class II APCs and lymphocytes 
(Stimulated MSCs may express HLA class II) 
*CD44 expression is characteristic of MSCs, with the exception of bone-marrow-native MSCs which are 
CD44-negative, however, when in culture, these cells acquire CD44 expression. 
 
MSC’s self-renewal potential allows for repeated passages with negligible changes to 
their characteristics (Friedenstein et al. 1974), though MSCs are usually only capable of 
expansion for about 25 population doublings (human multipotent adult progenitor cells, for 
example, share many similarities with MSCs but can be expanded for more than 70 
population doublings) (Bydlowski et al. 2009). MSCs can be driven to differentiate into 
specialized cells (Figure 3), through certain physiological/experimental conditions, but, 
again, to a lesser extent than typical adult stem cells or cord blood stem cells (for example, 
MSCs display very poor endothelial differentiation) (Uccelli et al. 2008). Furthermore, the 
in vitro characteristics of MSCs greatly depend on the culture conditions (Roobrouck et al. 
2011), which further complicates the elucidation of their in vivo characteristics. 
MSCs’ biological functions and properties within the tissues are not yet completely 
understood, but it has become increasingly clearer that MSCs are involved in the 
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maintenance of tissue homeostasis, possibly through the replacement of dead or 
dysfunctional cells and modulation of the activity of immune cells (Bydlowski et al. 2009, 
Pittenger et al. 1999). Thus, these cells are likely to represent a common component of 
natural ageing, tissue damage and immunological and inflammatory diseases. 
 
 
Figure 3. Mesenchymal stromal cell and differentiation markers. Theoretical hierarchy of 
mesenchymal stem cell differentiation. Myogenic differentiation ( ) has been demonstrated in 
vitro but not in vivo. From R&D Systems Tools for Cell Biology Research
TM
 (2014). 
 
The exact anatomical locations of MSC in situ are also not clear but, while they can be 
isolated from interstitial tissues, in vivo studies point to them residing mainly near blood 
vessels (Corselli et al. 2010, Crisan et al. 2008), surrounding arteries and veins. 
Additionally, Sachetti et al. (2007) isolated, from human bone marrow, MSCs that 
displayed high expression of CD146 (melanoma-associated cell-adhesion molecule) and 
represented a subpopulation of pericytes; a cell type present in virtually every organ, 
enveloping the surface of vascular tubes. Sachetti’s group took this to mean that tissue-
resident MSCs could be generated from the pericyte fraction in blood vessels, which is in 
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agreement with the observation that the majority of MSCs can be found in proximity to 
blood vessels. The hypothesis was further instilled by a study by Crisan et al. (2008) 
wherein MSCs were successfully isolated from several tissues based on the expression of 
surface antigens typical for pericytes, namely, CD146, NG2 and PDGFRβ. 
 
1.3.2. Migration, homing and involvement in tissue repair 
Tissue injury always leads to an inflammatory response with activation of immune cells 
(macrophages, neutrophils, lymphocytes and others), and their mobilization to the injured 
sites by the spilled contents from apoptotic and necrotic cells, damaged microvasculature 
and stroma, and secreted inflammatory molecules (cytokines and chemokines) (Eming et 
al. 2008, Luster et al. 2005). Mobilization of MSC to damage sites is already well known 
for many types of diseases (Otto & Wright 2011) and is thought to occur via similar 
mechanisms. MSCs can respond to some chemoattractants and they express chemokine 
receptors (Granero-Molto et al. 2008), but the identity of the chemokines that regulate 
their movement is still unknown. 
In vitro, MSC differentiation can be driven into a particular lineage by specific regulatory 
genes, treatment with growth factors, induction chemicals and culture microenvironment. 
Because they have the same embryonic origin, all MSCs share the ability to differentiate 
through mesoderm lineages both in culture and in vivo (Dominici et al. 2006). In vitro they 
are also capable of ectoderm differentiation (Ding et al. 2011) and endoderm 
differentiation, including the differentiation into pancreatic islet β-cells, pancreatic 
endoderm and pancreatic hormone producing cells (insulin, glucagon and somatostatin) 
(Lee et al. 2004), but these processes have not been confirmed in vivo. Furthermore, the 
MSC-derived cell populations do not fully mimic the biochemical and mechanical 
properties of the target tissue (Hwang et al. 2009), thus the MSC-mediated tissue repair 
may not be due to the replacement of damaged cells. Additionally, there is still an ongoing 
debate around MSC differentiation and regenerative abilities in vivo. Alternatively, when 
within the specific injury-related microenvironment, MSCs are stimulated by the typical 
low oxygen tensions, exogenous toxins and pro-inflammatory cytokines to aid in tissue 
repair via the release of paracrine factors (Table 4) (Aguilar et al. 2009, Amo et al. 2014, 
Bai et al. 2012).  
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Table 4. Summary of the hMSC-mediated regenerative effects and the main MSC-derived 
paracrine factors likely to be responsible. 
Growth Factor Contribution to hMSC-mediated therapeutic effects 
Ang-1 Angiogenesis and tissue repair (Chen et al. 2008) 
EGF Wound healing, tissue regeneration, neurogenesis (Kim et al. 2012) 
EPO Angiogenesis (Chen et al. 2008) 
FGF Tissue repair, intrinsic stem cell survival and regeneration (Arno et al. 
2014) 
HGF Vasculogenesis (Bai et al. 2012) 
IGF-1 Wound healing (Chen et al. 2008, Kim et al. 2012) 
KGF Wound healing (Aguilar et al. 2009, Chen et al. 2008) 
IL-8, 6 Wound healing (Kim et al. 2012) 
MIP-1α Wound healing (Chen et al. 2008) 
SDF-1 Neuroprotective effect, wound healing (Chen et al. 2008) 
TGFβ Wound healing (Arno et al. 2014) 
VEGF Angiogenesis and wound healing (Arno et al. 2014, Chen et al. 2008) 
Ang-1, angiopoietin-1; EGF, epidermal growth factor; EPO, erythropoietin; FGF, fibroblast growth factor; 
HGF, hepatocyte growth factor; IGF, insulin growth factor-1; KGF, keratinocyte growth factor; MIP-1α, 
macrophage inflammatory protein 1 alpha; IL, interleukin; SDF-1, stem cell-derived factor-1; TGFβ, 
transforming growth factor β; VEGF, vascular endothelial growth factor 
  
To further challenge the idea that MSC-mediated tissue repair is achieved through cell 
differentiation, Bartholomew et al. (2002), conducted an in vivo study on MSC-mediated 
tissue regeneration and, instead, revealed other surprising therapeutic properties; allogeneic 
MSCs did not elicit immune recognition and were capable of suppressing immune 
responses. The latter effect resulted from the inhibition of the activities and proliferation of 
several different immunocompetent cells, including T and B lymphocytes, NK cells and 
APCs, regardless of MHC compatibility and source of MSCs (Aggarwal & Pittenger 2005, 
Bartholomew et al. 2002, Klyushenkova et al. 2005, Ma et al. 2014, Tse et al. 2003, Zhang 
et at. 2004). Thus, besides their possible regenerative properties, MSCs possess strong 
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immunomodulatory activities, with great potential for application in the field of allogeneic 
transplantation and in the mitigation of immune disorders. 
 
1.3.3. Immunological profile and immunogenicity 
All MSCs, share the weak expression of MHC class I molecules and the lack of 
expression of MHC class II molecules and co-stimulatory molecules CD40, CD154 (CD40 
ligand), CD80 and CD86 (Le Blanc et al. 2003, Ma et al. 2014, Ryan et al. 2005). 
The absence of the molecules needed to activate T cell alloreactivity  is frequently used to 
explain the apparent immune-privilege of MSCs (Javazon et al. 2004), but several studies 
have shown that the expression of MHC class I and class II molecules can be up-regulated 
by IFNγ. However, IFNγ stimulation does not enhance MSC immunogenicity or the 
expression of co-stimulatory molecules (Klyushenkova et al. 2005). This would suggest 
that the lack of co-stimulatory molecules (even with IFNγ) is responsible for the 
preservation of the immune-privilege but, surprisingly, Tse et al. (2003) used MSC pre-
treated with IFNγ along with direct co-stimulation with anti-CD28 antibodies and still did 
not achieved a measurable T cell proliferative response. Therefore the reason why MSCs 
do not elicit T cell responses cannot be fully explained by the absence of co-stimulatory 
molecules. Nevertheless, IFNγ treatment mimics the inflammatory condition in vivo and 
shows that MSCs can be applied to alleviate inflammation, without loss of immune-
privilege, in inflammatory niches (Ma et al. 2014). 
 
1.3.4. Immunomodulatory potential 
 
Innate immunity; The MSC or CM-MSC mediated inhibition of monocyte 
differentiation to mature DCs appears to be irreversible (Spaggiari et al. 2009, Zhang et al. 
2004) and the resulting immature DCs have strongly reduced ability to stimulate T 
lymphocytes, up-regulation of anti-inflammatory cytokines, decreased pro-inflammatory 
cytokine production and the ability to promote the expansion of Treg cells (Aggarwal & 
Pittenger 2005, Jiang et al. 2005). 
MSCs express MHC class I molecules, but at low levels, which could make them 
susceptible to NK cell-mediated killing, but they are not lysed when in contact with resting 
NK cells. On the other hand, both autologous and allogeneic MSCs can be destroyed by 
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activated NK cells (Rasmusson et al. 2003, Spaggiari et al. 2006). Additionally, MSCs 
express surface ligands for activating NK cell receptors, but they can be made to 
successfully escape NK-cell mediated lysis by pre-treatment with IFNγ (Spaggiari et al. 
2006), which is not surprising seeing as IFNγ can enhance the expression of MHC class I 
molecules. Despite all of this, MSCs have global suppressive effect over NK cell activities, 
inhibiting their proliferative activity, cytotoxicity and cytokine production, in a dose 
dependent manner (Rasmusson et al. 2003, Spaggiari et al. 2006, Spaggiari et al. 2008). 
 
Adaptive Immunity; The effect of MSCs, or CM-MSC, leads to the inhibition of 
proliferation, differentiation into plasma cells (Asari et al. 2009, Corcione et al. 2006), 
expression of chemokine receptors (Corcione et al. 2006) and suppression of antibody 
production by activated B lymphocytes (Comoli et al. 2008, Corcione et al. 2006). 
Similarly, MSCs, even when separated from the target immune cells by a semi-permeable 
membrane, suppress the activation and proliferation of naïve and memory T cells activated 
by allo-antigens (Aggarwal & Pittenger 2005, Di Nicola et al. 2002), mitogens (Di Nicola 
et al. 2002, Le Blanc et al. 2004, Otto & Wrigth 2011) and stimulation with anti-CD3 and 
anti-CD28 antibodies, in a dose-dependent manner (Comoli et al. 2008, Krampera et al. 
2003). 
Allogeneic MSCs do not elicit T cell activation and both autologous and allogeneic 
MSCs are equally capable of suppressing T cell responses, suggesting that MSCs’ actions 
are independent from MHC compatibility (Aggarwal & Pittenger 2005). The hypothesis 
was confirmed by Klyushnenkova et al. (2005) by the demonstration of the inability of 
MSCs to promote T cell proliferation, even in the presence of cytokines with APC 
function, demonstrating the existence of an active immunossupressive mechanism. 
Interestingly, this ability to suppress T cell responses persists even after MSCs enter 
differentiation through the adipogenic, osteogenic and chondrogenic lineages (Le Blanc et 
al. 2003).  
MSCs are usually reported to suppress CD4
+
 and CD8
+
 effector T cell activation (English 
et al. 2010, Gieseke et al. 2010), often concomitantly with the stimulation of Tregs 
expansion. Gonzalez et al. (2009) observed that MSCs from human adipose tissue (AT-
MSCs) (autologous, allogeneic and xenogenic) suppressed the generation Th1 cells and 
stimulated the expansion of Treg cells, in an animal model for inflammatory bowel 
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disease. The group concluded that the reduction in Th1 cell numbers was a result of the 
increase of Treg cells and the exact same conclusion was drawn by an in vivo study 
wherein allogeneic mice MSCs induced normoglicemia in Th1 cell-mediated autoimmune 
diabetes mellitus in non-obese diabetic mice. In both cases, MSCs disfavored Th1 
polarization and increased the numbers of both CD4
+
 and CD8
+
 Treg cells (Madec et al. 
2009). And yet, Ribeiro and colleagues (2013) demonstrated that, when human peripheral 
blood mononuclear cells were co-cultured with allogeneic human MSCs from bone 
marrow (BM-MSCs), umbilical cord matrix (UCM-MDCs) or AT-MSCs, there was, 
indeed, favoring of T cell differentiation towards Treg, but, they also increased T-bet 
mRNA expression (a key transcription factor in Th1 differentiation) among non-activated, 
early activated, intermediate activated and later activated T cells, which reveals a 
polarization towards the Th1 phenotype. While the other mentioned studies assessed Th1-
mediated effector responses mainly by evaluating cytokine profiles (mostly IFNγ 
production), Ribeiro et al. (2013) used the more direct approach of investigating mRNA 
expression within different stages of T cell activation and, since, in the same study, MSCs 
hampered T cell activation, meaning that only a T few cells could undergo activation in the 
presence of MSCs, the group reasoned that, while the observed skewing towads Th1 cells 
seems to contradict previous works, the suppression of T cell activation would reduce 
overall IFNγ production. A gene expression analysis by Selleri’s group (2013) of T cells 
stimulated in the presence of MSCs also revealed a Th1 polarization. 
Furthermore, MSCs derived from human cord-blood have been shown to induce IL-10 
secretion by IFNγ producing Th1 cells, when T cells were stimulated with allogeneic 
mDCs in their presence, resulting in a concomitant increase of IFNγ and IL-10 production 
by activated T cells. Interestingly, in the same conditions, activated CD4
+
 T cells displayed 
reduced (bur not absent) responsiveness towards IFNγ due to the MSC-mediated 
suppression of the IFNγ receptor upregulation (a process that usually follows T cell 
activation), all the while the expression of the IL-10 receptor is not affected (Selleri et al. 
2013). 
There are not many studies focusing on particular T cell activation or differentiation 
stages, usually focusing on T cells in a broad sense, but the results from the 
abovementioned studies proved that the investigation of the MSCs’ concrete effects over 
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those stages would geatly contribute to the understanding of the mechanisms through 
which they affect T cell responses. 
The effect of MSCs in diseases with predominant Th2 cell responses has been scarcely 
studied, but MSC administration into mice with airway inflammation induced by 
ovalbumin (an allergen, which was given to allergy-prone mice to mimic allergic asthma) 
was reported to result in the decrease of the Th2 cell population along with the expected 
induction of Treg cells (Kavanagh et al. 2011). On the other hand, co-culture of CD4
+
 T 
cells with hMSCs resulted in suppression of the Th1 phenotype and promotion of the Th2 
phenotype (along with the induction of Treg cells) (Batten et al. 2006). Likewise, Bai et al. 
(2009) reported that, in a mouse model for multiple sclerosis, MSCs favored the 
polarization towards the anti-inflammatory Th2 cell responses, concomitantly with the 
suppression of Th17 and Th1 cell responses.  
Although there isn’t many data available, the existing experimental results indicate that 
MSCs can differentially regulate Th2 cell responses and the contrasting results are likely to 
be due to different inflammatory conditions, with MSCs having a inhibitory effect over the 
Th2 subset when the Th2 responses are more prominent (Kavanagh et al. 2011) and an 
enhancing effect when the far more aggressive Th1 and Th17 responses are dominant (Bai 
et al. 2009, Batten et al. 2006). However, the underlying regulatory mechanism is still 
unknown. Some of the more well accepted hypothesis are; indirect suppression of Th1 
responses through the inhibition of APCs (DCs in particular) (Duffy et al. 2011), 
promotion of the Treg phenotype (Duffy et al. 2011, Castro–Manrreza et al. 2015), and 
indirect skewing towards Th2 polarization due to the general reduction in IFNγ levels and 
increase in IL-10 levels (Castro–Manrreza et al. 2015). 
The study of MSC-mediated regulation of Th17 cell functions is also relatively recent. 
Ghannam et al. reported, in inflammatory conditions, induction of regulatory behavior in 
Th17 lymphocytes. These cells became capable of suppressing the proliferation of 
activated CD4
+
 T cells (Ghannam et al. 2010). Likewise, Wang et al. observed suppression 
of IL-17 production and Th1 cell responses with the stimulation of Th2 cell activities 
(Wang et al. 2008). More recently, MSCs from human bone marrow have been reported to 
reduce the percentage of T cells that express IL-17 when they were placed in co-culture 
with mononuclear peripheral blood cells, previous to and during T cell activation, which 
points to an inhibition, by MSCs, of Th17 differentiation (Laranjeira et al. 2015). 
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Conversely, MSC were reported to promote Th17 differentiation and suppressed Th1 
differentiation in vitro, but only when added 3 days after T cell activation (Carrión et al. 
2011), which suggests that the MSC effect depends on the stage of CD4
+
 T cell activation. 
The Th17 promotion along with Th1 suppression was also observed for CM-MSC, 
indicating the involvement of soluble mediators (Darlington et al. 2010).  
 
Table 5. Summary of the general actions of MSC over different T cell subsets. 
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Th2 and Th17 
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of Tc cell 
activation 
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mediated 
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       ; Th1/Th17 and Th17/Treg interconversion of relevance to MSC immunomodulatory 
effects (Duffy et al. 2011) 
 
MSCs have a consistent stimulatory effect over Treg cells; when CD4
+
 T cells are co-
cultured with MSCs there is an increase of Treg cell numbers (English et al. 2009). The 
same effect has been reported for several in vivo disease models including rheumatoid 
arthritis (Gonzalez-Rey et al. 2010) and organ allotransplantation, resulting in protection 
against rejection and prolonged graft survival (Casiraghi et al. 2008, Ge et al. 2010, Wang 
et al. 2009). 
MSCs avoid recognition and destruction by Tc cells and strongly suppress their activities, 
either directly or indirectly due to the general inhibition of T cell responses, which are 
required for Tc cell activation. Furthermore, MSCs can hamper both the generation and the 
activation of Tc lymphocytes, but, like in the case of NK cells, have little to no effect over 
the cytolytic activity of fully activated Tc cells (Rasmusson et al. 2003). Therefore, MSCs 
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may be ineffective against established CD8
+
 T cell effector functions; however MSCs are 
also capable of suppressive effects through the generation of CD4
+
 and CD8
+
 Treg cells, 
which can then amplify the MSC-mediated therapeutic actions. On the other hand, the 
MSCs may protect tumor cells from destruction due to the increase of Treg cells, Th2 cell 
responses and, especially, due to the suppression of Tc cells proliferation and activity 
(Patel et al. 2010). Thus, the in vivo study of these effects is still necessary to ensure that 
MSC-based treatments do not have severe side-effects in some patient groups.  
While the effect of MSCs over T cell responses has been extensively studied, a much 
lower number of studies have focused on the specific effect over each different T cell 
subpopulation individually (Table 5).  Additionally, there are very few studies focused on 
‘unconventional’ T cell subsets (γδ T and NKT cells) or in the effects over T memory cells 
(in comparison with effector cells). Furthermore, there are still many unknown details 
about the already established effects of MSCs over different T cell subsets, such as; i) 
considering that MSCs seem to strongly suppress Th1 cell responses (Bai et al. 2009, 
Gonzalez et al. 2009, Madec et al. 2009), while the effect over the Th2 phenotype is much 
more variable (Bai et al. 2009, Batten et al. 2006, Kavanagh & Mahon 2011), there might 
be an hierarchical influence over the three subsets (possibly Th1 > Th17 > Th2); ii) the 
apparent different levels of suppression over the Th subsets may be indicative of different 
regulatory mechanisms; iii) alternatively (or concomitantly) to the differential regulation of 
T cells, there may be different mechanisms of action among the heterogeneous populations 
of MSCs; iv) the significance of cell-cell contact in the modulation of T cell responses has 
not yet been studied in detail; v) the exact duration of the MSC-mediated effects is 
unknown, and vi) there is not yet a means to accurately determine the immunossupressive 
potency before MSC administration. 
There is multitude of different cell types and subtypes, with diverse functions, and those 
actions have different weight in different pathological states, therefore, the assessment of 
MSCs’ true therapeutic potential, and possible draw-backs, still requires further 
investigation regarding their effects over different T cell subpopulations, especially in light 
of the fact that MSCs have been recently reported to differentially regulate distinct T cell 
subsets (Laranjeira et al. 2015). 
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1.3.5. Mechanisms of action 
MSCs gathered considerable attention in the improvement of wound healing and have 
been successfully employed in this context by several studies spanning many different 
diseases. However, the percentage of administrated cells that actually engrafts at the site of 
damage seems to be fairly small as the majority of MSCs either migrate into the lungs and 
liver or enter apoptosis, disappearing rapidly after administration. And yet, their short-lived 
presence still yields therapeutic results (Askari et al. 2003, Lee et al. 2009, Wang et al. 
2012). It is also quite unclear if differentiation is indeed the main mechanism behind the 
tissue repair (Murry et al. 2004).  
Several groups were able to achieve therapeutic results using MSCs or CM-MSC alone 
(Gnecchi et al. 2006, Shabbir et al. 2009, Song et al. 2014) and proposed that the 
mechanisms responsible for the therapeutic effects of MSC were mainly the result of the 
secretions of these cells (Figure 4). The hypothesis is supported by the fact that engrafted 
MSCs have been shown to produce growth factors and cytokines that promote tissue repair 
(Amo et al. 2014, Aguilar et al. 2009, Bai et al. 2012).  
Ren et al. (2008) reported that MSC can be stimulated to produce high levels of 
immunosuppressive factors by IFNγ in combination with one of the pro-inflammatory 
cytokines TNFα, IL-1α or IL-1β. This stimulation also results in the up-regulation of the 
expression of chemokines and adhesion molecules (Ren et al. 2008, Ren et al. 2010) 
resulting in an accumulation of immune cells in proximity to MSCs, forming a specific 
localized microenvironment which amplifies the effect of MSC-derived mediators. 
Because of this, Aronin & Tuan (2010) proposed that naturally occurring MSCs’ main role 
in tissue injury is to suppress immune responses and to trigger several healing-promoting 
processes through the secretion of soluble factors (Figure 4). 
Studies focused on the identity of the soluble factors responsible for MSC-mediated 
immunomodulation have pointed to many suitable candidates (Table 6). However, 
contradictory results are very frequent, although possibly just due to external factors such 
as the type of responder population and type of stimuli, both of which could influence the 
immunosuppressive mechanism of MSC.  
HGF-1 has been found in high levels in CM-MSC and has been reported to have a crucial 
role in the protective effects of CM-MSC against experimental autoimmune 
encephalomyelitis (EAE), the mouse model for multiple sclerosis (Bai et al. 2012). TGFβ 
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is a powerful immunosuppressive molecule involved in immune privilege (Raghupathy 
2001, Smith et al. 2012, Tompkins et al. 1998) and TGFβ secretion has been demonstrated 
for MSC from multiple sources (Zhou et al. 2011, Melief et al. 2013, Yoo et al. 2013) and, 
in some cases, anti-TGFβ antibodies or TGFβ silencing can reverse MSC-mediated 
inhibition of lymphocyte proliferation (Yoo et al. 2013). Di Nicola et al. (2009) reported 
the involvement of TGFβ and HGF-1 in MSC-mediated immunosuppression and managed 
to partially rescue activated T cell proliferation with TGFβ and HGF neutralizing 
antibodies. On the other hand, three different in vitro studies (Bai et al. 2012, Le Blanc et 
al. 2004, Plumas et al. 2005), reported that there was no involvement of TGFβ or HGF-1. 
However these groups focused on T cells activated by mitogens or by using peripheral 
blood mononuclear cells as responder cells while Di Nicola’s group used T cell activation 
by allogeneic peripheral blood lymphocytes. Additionally, in Di Nicola et al’s study the 
suppressive effect was transient while a study by Glennie et al. (2005) verified the arrest of 
T cells at the G0/G1 phase of the cell cycle, but the group used murine MSCs while Di 
Nicola and colleagues worked with cells of human origin.  
These results are consistent with the established notion that the immunosuppressive 
mechanisms of MSC depend on the source from which they were isolated. Furthermore, 
the intervenient soluble molecules are not universal, varying from species to species (Ren 
et al. 2009). For example, the mechanism of action of murine MSCs seems to be largely 
dependent on nitric oxide (NO), an immune suppressor at high concentrations (Sato et al. 
2007), but for hMSC the role of NO is replaced by indoleamine 2,3-dioxygenase (IDO), an 
enzyme involved in the degradation of the essential amino acid tryptophan (Sioud et al. 
2011,  Xy et al. 2007). IDO is not constitutively produced by MSCs, but its expression is 
induced by certain conditions, such as IFNγ stimulation (Meisel et al. 2004). Since 
tryptophan depletion alone cannot fully explain the inhibitory effect of MSC (Tse et al. 
2003) the IDO-mediated immune suppression is thought to be mainly due to local 
accumulation of tryptophan metabolites (Mellor & Munn 2004). 
Several studies support that PGE2 has a crucial role in the modulation of inflammatory 
responses by MSC, having proven that COX inhibitors can decrease MSCs’ therapeutic 
effects (Dhingra et al. 2013, Rasmusson et al. 2005, Zhang et al. 2013). Interestingly, 
Rasmusson and colleagues (2005) abrogated MSC-mediated immunosuppression with an 
inhibitor of PGE2 synthesis, but reported that cell proliferation was only restored for 
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mitogenic activation and not for a mixed lymphocyte reaction (MLR), thus other inhibitory 
pathways were involved in the latter condition, which could mean that the mechanisms of 
suppression of activated T cell proliferation by MSCs differs with the type of activating 
stimuli. On the other hand, high PGE2 concentrations can have pro-inflammatory effects, 
partially due to the diversity of PGE2 receptors (Kalinski 2012), illustrating how MSCs’ 
activities may have great underlying complexity. 
 
Table 6. Summary of factors possibly involved in hMSC-mediated immunosuppression. 
Soluble factor Effects on immune cells 
Galectin-1/-9 Induction of activated T cell apoptosis (Barondes et al. 1994) 
HLA-G5 Suppression of NK cell activity; 
Inhibition of T cell proliferation; 
Promotion of Treg cell generation (Selmani et al. 2008) 
HGF-1 Inhibition of CD80 and CD86 expression by DCs; 
Suppression of Th1 cell responses and induction of Treg cells (Chabannes 
et al. 2007, Gu et al. 2013) 
HO-1 Inhibition of T cell activation; 
Promotion of Treg cell generation; 
Promotion of IL-10 and TGFβ release by Treg cells (Lee et al. 2002) 
IDO Inhibition of T cell responses (Meisel et al. 2004, Mellor & Munn 2004, 
Ren et al. 2009, Spaggiari et al. 2008) 
Enhancement of PGE2 inhibitory effects (and vice-versa) (Spaggiari et al. 
2008). 
PGE2 Inhibition of T cell proliferation; 
Promotion of of Th2 cell responses (Woorlard et al. 2007) 
Induction of Treg cells (Baraelli et al. 2005) 
Inhibition of Th1 cell responses (Dohadwala et al. 2005, Snijdewint et al. 
1993) 
Suppression of Tc, NK and Th1 cell activation (Dohadwala et al. 2005, 
Spaggiari et al. 2008) 
Inhibition of DC maturation and macrophage activity (Baraelli et al. 2005, 
Lee et al. 2002, Spaggiari et al. 2009) 
Enhancement of IDO inhibitory effects (and vice-versa) (Spaggiari et al. 
2008) 
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PDL-1 Suppression of  Th17 cell responses; 
Inhibition of T cell proliferation (Snijdewint et al. 1993) 
TGFβ Inhibition of DC maturation (Gandhi et al. 2008) 
Induction of Treg cells (Kushwah et al. 2010) 
Suppression of Th17 cell generation (Romagnani 2008) 
Generation and maintenance of IL-10 producing Th1 cells (Huss et al. 
2011) 
TSG-6 Counteracts the effects of TNFα and IL-1 (Wisniewski & Vilcek 2004) 
Exosomes and 
microvesicles 
Transfer of miRNAs, KGF, anti-inflammatory proteins and mitochondria 
(Bruno et al. 2009, Gatti et al. 2012, Islam et al. 2012, Li et al. 2013, 
Raymond et al. 2009, Zhu et al. 2014) 
Cell-Cell contact Inhibition of T cell activation (Krampera et al. 2003) 
HLA-G5, Human leukocyte antigen G5; HGF-1, Hematopoietic growth factor-1; HO-1, hemeoxygenase-1; 
IL-6, Interleukin 6; IDO, Indoleamine 2,3-dioxygenase; miRNA, micro-RNA, PDL-1, Programmed cell 
death ligand 1; PGE2, Prostaglandin E2; TGFβ, transforming growth factor β; TSG-6, tumor necrosis factor-
stimulated gene-6 
 
MSCs are thought to be capable of IL-10 production, but the involvement of this anti-
inflammatory cytokine in MSC-mediated regulation of immune responses is still 
controversial and a few studies have reported that neither MSCs alone nor LPS/IL-3 
stimulated MSCs secrete IL-10 (Groh et al. 2005, Rasmusson et al. 2005). Moreover, 
blocking IL-10 does not seem to affect the immunosuppressive effect of MSC over B and 
T lymphocytes (Xu et al. 2007) so the increase in IL-10 levels in the presence of a 
population of MSCs and immune cells, might solely be a product of the latter.  
Human MSCs can produce TSG6, particularly if stimulated by TNFα, and TSG-6 
depletion results in the diminished ability to suppress immune responses (Lee et al. 2009). 
Recently galectins have also been included to the group of regulators likely to be 
responsible for MSCs’ immunosuppressive potential (Sioud et al. 2011) and both galectin-
1 and 9 knockdown MSCs have their inhibitory effect over CD4
+
 and CD8
+
 T cells 
dampened (Gieseke et al. 2010, Gieseke et al. 2012). Soluble HLA-G5, also involved in 
AM-mediated immunosuppression, is produced and released by MSCs following contact 
with alloreactive T lymphocytes (Ryan et al. 2005, Selmani et al. 2008).  
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Figure 4. Proposed model for biological functions and mechanisms of action of MSCs in 
response to tissue damage and/or infection. Transdifferentiation may occur in vivo but is not the 
main mechanism underlying MSC-mediated therapeutic effects, instead, the endocrine/paracrine 
secretion of regenerative and immunossupressive factors, independently of the anatomical location, 
promotes tissue repair and protects the host against inflammation damage. No one mechanism of 
immunomodulation is prevalent, instead, MSC possess a redundant panel of numerous pathways, 
some of which act in synergy. Solid (  ) and dashed lines (  ) represent direct and indirect 
effects, respectively, the arrows (  ) represent stimulation and the end-circles (  ) inhibition. 
 
Lastly, cells can communicate through the release of exosomes and/or microvesicles that 
transport high concentrations of proteins and other molecules within them. They are small 
portions of cytoplasm formed by budding of the cell membrane into small vesicles; 50 nm 
to 1000 µm in size for microvesicles and 40 to 100 nm for exosomes. MSCs are capable of 
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bidirectional communication between injured tissue and cells with regenerative potential, 
through shuttling of microvesicles containing various bioactive molecules along with 
coding and non-coding RNAs and even mitochondria (Bruno et al. 2009, Gatti et al. 2012, 
Zhu et al. 2014). hMSC-derived microvesicles have been reported to be associated with 
protection against immunological disorders (Bruno et al. 2009, Gatti et al. 2012, Zhu et al. 
2014). Likewise, some groups have implicated the involvement of exosomes in MSC-
mediated therapeutic effects (Li et al. 2013, Raymond et al. 2009). However the role of 
MSC-derived exosomes is a new topic of investigation and is not yet established. 
Several other soluble factors have been suggested to have some importance in MSC-
mediated immunoregulatory activity but, in contrast, Krampera et al. (2003) reported that 
the suppression of T cell responses relied on direct cell-cell contact, through which MSCs 
physically blocked the interaction between inactive, naïve or memory, T cells and APCs 
thus preventing T cell activation. However it is important to note that these results did not 
include the effects of MSCs over activated effector T cells. 
 
1.3.6. Modulation of MSC behavior 
The exact properties and effects of MSCs over immune cells change drastically 
depending on culture conditions, leading to initial studies often resulting in contradictory 
results. Thus, it has become clear that the modulation of immune responses by MSC may 
not be constitutive but, instead, context-dependent (Dazzi & Krampera 2011).  
To highlight this aspect; frequently, different studies focusing on the same disease report 
MSCs to have divergent effects, with one study indicating improvement while another 
observes the aggravation of the pathological condition (Augello et al. 2007, Djouad et al. 
2005), especially when there is a significant difference in the timing of MSC 
administration (since the inflammatory environment changes along the development of the 
disease). Thus, the patient’s response to MSC-based treatment could, in theory be assessed 
by examining the pathologic microenvironment before treatment. Because of the great 
impact this has on the clinical applications of MSC it becomes necessary to understand the 
mechanisms that regulate immune modulation by MSC. 
In general, conditions associated with tissue damage, such as low oxygen tensions and 
high pro-inflammatory cytokine levels, seem to strongly enhance the regenerative and 
immunosuppressive activities of MSCs (Table 7), but many other culture conditions can 
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also affect the therapeutic potential of MSCs, for instance, comparatively to the standard 
monolayer culture, MSCs in micro-emboli of myocardial infracted mice or in a hanging 
drop system, produce higher levels of TGS-6 (Bartosh et al. 2010, Lee et al. 2009) and the 
CM-MSC or MSCs of spheroid cultures have their anti-inflammatory effect significantly 
enhanced (Bartosh et al. 2013, Ylöstalo et al. 2012) (Table 7). This type of self-stimulation 
has also been shown to occur naturally in vivo as a result of the MSCs’ tendency to self-
aggregate (Bartosh et al. 2013, Lee et al. 2009). 
 
Table 7. Summary of the effects of hypoxia, pro-inflammatory stimuli and 3-dimentional cultures 
conditions over the paracrine actions of MSCs. 
Condition Modulation of MSC behavior Up-regulated paracrine 
factors 
Hypoxia   
(1-2% O2)  
Stimulation of the production and 
release of paracrine factors 
(Chang et al. 2013, Crisostomo 
et al. 2008, Efimenko et al. 2011, 
Iida et al. 2010, Rasmussen et al. 
2011); 
Promotion and maintenance of 
stem cell potency (Hawkins et al. 
2013, Iida et al. 2010) 
FGF, VEGF, IGF, HGF, IDO 
(Chang et al. 2013, Crisostomo et 
al. 2008, Efimenko et al. 2011, 
Iida et al. 2010, Rasmussen et al. 
2011) 
Inflammatory stimuli 
(IFNγ, TNFα, LPS) 
Up-regulation of the expression of 
soluble factors (Crisostomo et al. 
2008, Croitoru-Lamoury et al. 
2011, Gieseke et al. 2013)  
VEGF, HGF, IDO, TGFβ, PGE2, 
Galectin-9, TSG-6, 
microvesicles/exosomes 
(Crisostomo et al. 2008, 
Croitoru-Lamoury et al. 2011) 
3D culture 
configuration 
Stimulation of the production and 
release of trophic factors (Bartosh 
et al. 2010, Lee et al. 2009, 
Ylöstalo et al. 2012) 
PGE2, TSG-6 (Bartosh et al. 
2013, Lee et al. 2009, Ylöstalo et 
al. 2012) 
 
The effectiveness of MSC administration will also depend on other factors; first of all, the 
method of MSC delivery result is known to affect the therapy outcome, both in terms of 
engraftment and therapeutic efficiency (Castelo-Branco et al. 2012, Freyman et al. 2006), 
consequently, the selection of the appropriate route of MSC administration for the 
treatment of a given pathological condition is vital for the success of the treatment. 
Secondly, an insufficient dose of MSC will not yield significant results, but above a certain 
dosage the therapeutic effect cannot be improved (Wu et al. 2008). On the other hand, too 
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early of a delivery, at an early stage of an inflammatory disease, reduces the therapeutic 
effects of the immunosuppressive activities of MSC, but, when it comes to MSC 
engraftment, injection at early stages of ischemia or EAE, produces greater therapeutic 
results than if MSC are administrated at the relapse stage (Constantin et al. 2009, Rafei et 
al. 2009).  
Therefore, in order to assess the true potential of MSC as therapies, pre-clinical 
experiments and clinical trials need to take into consideration multiple factors that affect 
their behavior including, not only the source of MSC, number of administrated cells and 
the correct timing of cell delivery, but also several aspects of the culture conditions 
previous to administration. 
 
1.3.7. MSC licensing and the balance between pro- and anti-inflammatory behavior 
Although MSCs habitually display immunossupressive effects it is thought that, in vivo, 
in their inactive state (without stimuli), MSCs mainly have an anti-apoptotic and 
supportive effect over many different cell types, including hematopoietic stem cells (Dazzi 
et al. 2006), immune cells (Benvenuto et al. 2007) and neoplastic cells (Kamoub et al. 
2007). Additionally, certain conditions can prevent the achievement of MSC 
immunosuppressive effects or lead to an MSC-mediated enhancement of the immune 
response. Remarkably, MSCs can even display antigen-presenting abilities when induced 
by low IFNγ levels (the exact concentration value varies greatly from study to study) 
(Chan et al. 2006, Romieu-Mourez et al. 2009). Because of this inducible antigen 
presenting ability, Romieu-Mourez et al. (2009) pointed out that MSC could be candidates 
for the treatment of cancer and infectious diseases through the activation of antigen-
specific cytotoxic CD8
+
 T cells, although the subject is considerably new and still under 
study. The failure to obtain immunossupressive effect, whether due to wrong timing of 
administration in vivo or inadequate stimuli in vitro/in vivo, is, therefore, explained by the 
absence of successful MCS licensing (Auletta et al. 2012, Chinnadurai et al. 2014). 
Since the inhibitory effect of MSCs is not constitutively expressed, the attainment of an 
anti-inflammatory behavior depends on a licensing step, which is a complex, multi-step 
process that ultimately results in the functional maturation of MSCs. The maturation 
towards an immunossupressive phenotype will depend on the activation, via pro-
inflammatory stimuli, and the prevalence of those stimuli over other signals that may 
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hamper the inhibitory effect of MSCs. It is likely that the MSC licensing involves the 
induction of specific transcription factors by molecular signals within the 
microenvironment, in a manner similar the signaling pathways that drive T naïve cells to 
differentiate into different T cell subsets. Additionally the switch between supportive, anti- 
and pro-inflammatory effects probably occurs via the modification of intracellular 
pathways by certain cytokines and other factors (Auletta et al. 2012). 
 
Table 8. Possible progression of MSC activities during infection. 
Immune system MSC main functions 
0. Resting state Supportive role over hematopoietic stem cells and 
immune cells 
1. Pathogen/damage detection Recruitment to site of infection 
2. Activation of immune 
responses 
Enhancement of anti-microbial and pro-inflammatory 
functions of immune effector cells 
3. Pathogen Elimination 
 
Enhancement of anti-microbial and pro-inflammatory 
functions of immune effector cells → Production of 
immunosuppressive and regenerative soluble factors 
4. Return to resting state Modulation of inflammation 
Promotion of wound healing, tissue repair and re-
vascularization 
 
The functional plasticity of MSCs is thought to be crucial for the maintenance of 
homeostasis. The local levels of cytokines, chemokines, oxygen radicals and low oxygen 
tensions (pro-inflammatory stimuli) vary depending on many factors, mainly; pathogen 
burden, inflammatory soluble factors and longevity of the response. In that sense, MSCs 
may work as ‘sensors’ to detect changes in the microenvironment and react accordingly 
(through the modulation of innate/adaptive immune responses and tissue repair), for 
instance, MSCs would, theoretically, react to the initial stages of the immune response to 
infection by stimulating immune effector cells, thus decreasing the pathogen burden (Table 
8) (Auletta et al. 2012, Singer & Caplan 2011, Waterman et al.2010). 
Regarding the mechanisms behind the stimulation of immune responses; MSCs have 
been shown to produce, under certain conditions, IL-6 and IL-8, both of which contribute 
for T cell activation (Waterman et al. 2010). Additionally, MSCs at low concentrations of 
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IFNγ are capable of activating Tc cells by antigen presentation in complex with a MHC 
class I molecule, instead of class II; a property typical of DCs known as antigen cross-
presentation (Romieu-Mourez et al. 2009). 
 
 
 
Figure 5. A shematic representation of the functional plasticity of MSCs. During the first stages 
of the response to infection/injury (or in cases of chronic inflammation), the low levels of 
inflammation (insufficient inflammatory cytokines) lead MSCs to display a pro-inflammatory 
behavior (MSC1) that increases the activity of immune effcetor cells, stimulating the removal of 
the infection (or worsening the disease state in case of chronic inflammation). Vigorous 
inflammation, on the othe hand, licenses MSCs to display an anti-inflammatory and regenerative 
behavior (MSC2) to prevent tissue damage and maintain the homeostasis. The arrows (  ) and 
end-circles (  ) represent stimulation and inhibition, respectively. 
 
After the initial pro-inflammatory effect, as the inflammation becomes more vigorous and 
persistent, in order to maintain the host’s integrity, MSCs can then exhibit an 
immunossupressive behavior to attenuate systemic inflammation and to promote tissue 
repair (Table 8) (Auletta et al. 2012, Singer & Caplan 2011, Waterman et al.2010). 
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Thus, MSCs are involved in the host protection in more ways than one, supporting 
hematopoiesis, mobilizing and stimulating immune effector cells and modulating 
inflammatory processes to prevent tissue damage (Figure 5). However the information 
regarding exact activating and inhibitory signal or signals, along with the level of 
inflammatory stimuli at which the MSC switch from pro- to anti-inflammatory behavior, is 
still considerable new and lacking. 
 
1.3.8. Some other frequent concerns  
A few other issues still need addressing before the successful clinical application of 
MSCs can be guaranteed. One of these concerns is that MSC-based therapies may lead to 
the loss of the normal protective function of the immune system. However, given that the 
inhibitory effects of MSCs are only present if licensed by acute, vigorous, persistent 
inflammation, and that MSCs can modulate their behavior according to physiological 
needs (Auletta et al. 2012, Singer & Caplan 2011, Waterman et al.2010), MSC-based 
therapies have an advantage over other immunossupressive therapies because they are less 
likely to increase susceptibility to infection. Additionally, results from clinical trials 
focusing on the treatment of graft-versus-host-disease (GvHD) have shown that normal, 
and effective, anti-viral immune responses remain at large in spite of the therapy (Ball et 
al. 2007, Le Blanc et al. 2008). 
Also in the treatment of GvHD, MSC-mediated immune inhibition may affect the graft-
versus-leukemia effect (GvL), and effect of MSCs has been reported by a few studies 
wherein MSCs administration ameliorated the GvHD condition but also seemed to increase 
the frequency of disease relapse in malignant hematological patients after allogeneic 
hematopoietic stem cell transplantation (Ning et al. 2008). On the other hand, Selleri et al. 
(2013), in light of their findingds (detailed in section 1.3.4), have hypothesized that MSCs 
can treat GvHD without inhibiting the beneficial GvL effect since T cell responsiveness to 
IFNγ, demonstrated to facilitate the GvL effect (Yang & Sykes 2002), is reduced, but not 
abolished, and Treg cells, whose differentiation and expansion is promoted by MSCs, can 
suppress GvHD without decreasing the GvL effect. Aditionally, it is always important to 
consider that the outcome of MSCs-based therapies will greatly depend on multiple 
factors, such as the point in the disease progression at which they are administred.  
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There is also the question of whether MSCs can be affected by previous or concurrent 
administration of immunosuppressive drugs, or other therapies. This issue has been raised 
by several groups, and has produced many clashing results (Buron et al. 2009, Eggenhofer 
et al. 2011, Inoue et al. 2006), but it is possible that those differences may simply derive 
from other factors that influence MSCs’ behavior. More recently, Girdlestone et al. (2015) 
demonstrated that MSC could be made up to 5-fold more proficient in the inhibition of T 
cell proliferation if pre-treated with one of four different immunosuppressant drugs, 
namely; rapamycin and everolimus, which are inhibitors of the mTOR pathway 
(mechanistic target of rapamycin, or mTOR, is a protein with a fundamental in the 
regulation of cell cycle progression), and the calcineurin inhibitors (calcineurin is involved 
in the induction of transcripton of IL-2 and other cytokines) tacrolimus and cyclosporine 
A. The group also demonstrated that this effect was likely due to the ability of MSCs to 
absorb the drug, during pre-treatment, and then act as a drug delivery system. Interestingly, 
cyclosporine A required higher doses to improve MSC-mediated immunosuppression than 
the other drugs, and, for all immunosuppressants, this effect could not be enhanced above a 
certain dose (Girdlestone et al. 2015). Thus, MSC-based therapies could greatly benefit by 
the definition of appropriate drug combinations. 
On the whole, in spite of these gaps and others that may not have been yet revealed, 
clinical studies regard MSC-based therapies as feasible and safe. Nevertheless, before the 
implementation of MSC-based immunotherapies, it is important to understand how they 
are influenced by external factors, which immune cells their act on and how these cells are 
affected. Additionally, while short-term safety seems to be a certainty, data concerning 
long-term safety is still lacking along with the establishment of the suitable dosage. 
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2. THE HUMAN AMNIOTIC MEMBRANE AS A SOURCE OF 
MESENCHYMAL STROMAL CELLS 
 
The hAM is composed of only two cell types (excluding fetal-derived macrophages 
[Bourne 1962, Casey & MacDonald 1996, Grigoriadis et al. 2013]); amniotic epithelial 
cells, derived from the embryonic ectoderm, and mesenchymal cells, derived from the 
embryonic mesoderm, dispersed among the collagenous stromal layer that underlies the 
amniotic epithelium (Alviano et al. 2007, Lindenmair et al. 2012).  
At the earlier stages of embryogenesis the amniotic epithelial layer is immediately 
adjacent to the mesenchymal layer, however, as collagen is deposited between the 
epithelial and mesenchymal cells, the two become separated by an acellular, collagenous 
compact layer (Casey & MacDonald 1996), therefore, while hAM-derived MSCs can be 
isolated from first-, second-, and third-trimestre amnion mesoderm, pure fractions are more 
easily obtained from human term placenta, after mechanic separation of the hAM from the 
chorion, by enzymatic digestion with collagenase (Parolini et al. 2008, Lindenmair et al. 
2012). But, while the expansion rate of epithelial cells can maintain a continuous epithelial 
layer throughout the growth of the amniotic sac, mesenchymal cells have a lower growth 
rate and thus become dispersed within a loose network of connective tissue. Generally, 
each gram of amnion tissue can yield roughly 1 to 2 × 106 MSCs, approximately 10-fold 
less than the number of amniotic epithelial cells (Casey & MacDonald 1996, Alviano et al. 
2007). 
The bone marrow is still the most well-known source of MSCs, however, the isolation 
process is highly invasive and this population represents less than 0.1% of the nucleated 
cells and tends to decrease with age (Alviano et al. 2007, Bieback & Brinkmann 2010, 
Alikarami et al. 2015). On the other hand, perinatal tissues, such as the placenta and its 
membranes, are considerably richer sources of MSCs than most somatic tissues (Alviano et 
al. 2007, In ‘t Anker et al. 2004, Miki 2011). For instance, Alviano and colleagues (2007) 
found that, comparativey to the human bone marrow, a greater number of MSCs could be 
obtained when hAM was used as the source tissue, additionally, only a very small area of 
amniotic membrane, less than 1/300 of the total area, was needed to achieve significant 
MSC quantities. In the same study, it was also reported that the hAM-derived MSCs 
exhibited higher proliferation capacity in comparison to the bone marrow-derived adult 
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MSCs, a property that had already been demonstrated for human placenta-derived fetal 
MSCs (In ‘t Anker et al. 2004). This superior expansion potential had a great contribution 
for the final cellular yield; the group observed that, at each point in time during culture, the 
number of bone marrow-derived MSCs was lower than the number of hAM-derived 
MSCs, and the latter increased, approximately, 300-fold during 21 days of culture (Alviano 
et al. 2007).  
Another noteworthy advantage of postnatal gestational tissues is the easy access through 
completely non-inasive methods, since they are generally discarded at birth, 
consequentely, cell harvesting presents no risk to the donor,  these tissues are, in theory, in 
unlimited supply and are not associated with any major ethical issues (Bieback & 
Brinkmann 2010, Hass et al. 2011). 
Furthermore, given that the supporting connective tissue of the AM completely lacks 
vasculature, smooth muscle, lymphatic tissue and nervous tissue, the amnion is the only 
source of MSCs without contamination from non-fibroblastoid cells (Alviano et al. 2007, 
Casey & MacDonald 1996). Conversely, culture of placenta or umbilical cord-derived 
MSCs is often associated with contamination from hematopoietic and endothelial cells 
(Alviano et al. 2007). 
Several studies have suggested that MSCs derived from birth-associated tissues possess 
superior biological properties in comparison with MSCs originated from adult tissues; the 
most important of which is that MSCs originated from neonatal tissues display less 
environmental and age-related DNA damage (Miki 2011, Steindler & Pincus 2002). 
Additionally, the aforementioned study by Alviano et al. (2007) reported that hAM-derived 
cells had higher expression levels of octamer-binding transcription factor 4 (Oct-4, a 
transcription factor involved in the self-renewal of totipotent embryonic cells) than bone 
marrow-derived MSCs. 
Finally, although MSCs derived from the bone marrow, and other commonly studied 
sources, only display immunosuppressive properties when cultered with activating stimuli, 
such as pro-inflammatory cytokines (Chinnadurai et al. 2014), recently, it has been shown 
that immunomodulation by hAM-derived MSCs does not require previous stimulation; for 
instante, Pianta et al. (2015) reported that, even without stimulating culture conditions, 
conditioned medium derived from MSCs isolated from the mesenchymal layer of the hAM 
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suppressed CD4
+
 and CD8
+
 T lymphocyte proliferation induced by allogeneic target cells 
or through T-cell receptor engagement. 
The intrinsic immunosuppressive properties of hAM-derived MSCs, along with their 
distribution throughout the amniotic membrane, lead to the speculation that these cells are 
involved in the maternal immune tolerance to the fetus (Magatti et al. 2008) and, the 
discovery of the possible involvement of MSCs in scarless fetal wound healing seems to 
support this hypothesis (Hu et al. 2014). Scarless fetal wound healing is a process intrinsic 
to the fetus dring early gestation which allows regeneration of fetal skin wounds absent of 
inflammation and scarring, through a not yet fully understood mechanism (Hu et al. 2014). 
However, the contribution of MSCs for these processes is only speculative and the 
hypothesis is still under study.  
Overall, term hAM appears to be an ideal source of MSCs; it is redily available from each 
delivery, ethically acceptable, the isolation procedure is relatively easy with high recovery 
efficiency and hAM-derived MSCs may have superior biological properties, such as higher 
expansion potential and less DNA damage. However, it still remains to identify what 
immune cells are affected by hAM-derived MSCs, how they are affected and what are the 
key underlying mechanisms. 
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3. OBJECTIVES 
 
The aim of this work was to evaluate the modulatory effect of a hAM extract (hAME), an 
enriched mixture of hAM-derived factors, over specific CD4
+
 and CD8
+
 T cells subsets in 
order to determine wether or not the different functional compartments were differentially 
regulated. Hence, the following defined objectives were established; 
 
i) Phenotypic characterization of hAM-derived cells.  
 
ii) Assessment of the effect of hAME over lymphocyte proliferation. 
 
iii) Evaluation of the effects of hAM-derived cells over the frequency of CD4
+
 and CD8
+
 
T cells that produce inflammatory cytokines (TNFα, IFNγ, IL-2, IL-17 and IL-9) among 
different functional compartments (naïve, central memory, effector memory and effector). 
 
iv) Evaluation of the effects of hAME over the frequency of CD4
+
 and CD8
+
 T cells that 
produce inflammatory cytokines among the same T lymphocyte subpopulations. 
 
v) Analysis of the effects of hAME over mRNA expression in purified CD4
+
 T cells, 
CD8
+
 T cells, Treg cells and Tγδ cells. 
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4. MATERIALS AND METHODS 
 
4.1. Source of the hAM extract 
The hAM-derived cells and hAM extract (hAME) used in the experiments were received, 
ready-for-use, from the Faculty of Medicine of the University of Coimbra (Coimbra, 
Portugal); the basic methodology of hAM cells isolation and extract preparation is 
described below. 
 
4.1.1. hAM reception 
hAM were obtained at the Coimbra Hospital and University Centre (Coimbra, Portugal) 
from 6 healthy women after elective caesarean sections with informed consent according to 
the guidelines of the Ethical Committee of the Coimbra Hospital and University Centre. 
hAM was mechanically peeled from the chorion and washed with phosphate buffered 
saline (PBS) with 2% antibiotic-antimycotic (Sigma-Aldrich, St. Louis, Missouri, USA). 
One portion of hAM was used to prepare the hAM extract (hAME), and other portion was 
used to isolate hAM-derived cells. 
 
4.1.2. hAME preparation 
hAM was briefly placed on PBS and then minced, homogenized, sonicated and 
centrifuged (14000 x g for 15 minutes) on ice. The supernatant was collected and stored at 
-80ºC until protein quantification in NanoDrop (ND-1000 Spectrophotometer, Wilmington, 
Delaware, USA). No detergents were used for hAME preparation to avoid any interference 
in the in vitro results. 
The final protein concentration of hAME was approximately 3.7 ± 0.2 mg per mL. 
 
4.1.3. hAM-derived cells isolation, culture and characterization 
hAM were incubated for 7 minutes at 37
o
C under stirring in 50% dispase (Stem Cell 
Technologies, Vancouver, Canada), and 50% PBS. hAM was then subjected to a resting 
period of 8 minutes at room temperature (RT, 18
o
C) in Dulbecco's Modified Eagle 
Medium (DMEM) (Sigma-Aldrich) pH 7.4,  with 10% heat-inactivated fetal bovine serum 
(FBS) (Sigma-Aldrich), 0.25% sodium pyruvate (Gibco, Life Technolgies, Paisley, UK) 
and 2mM of L-Glutamine (Sigma-Aldrich). Afterwards, hAM was totally digested at 37
o
C 
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under stirring in an enzyme cocktail composed by 0.75mg/mL collagenase IV (Gibco), 
20µg/mL DNAse I (Sigma-Aldrich), 3mM calcium chloride (Sigma-Aldrich) and 0.25% 
trypsin (Sigma-Aldrich) in PBS. After total digestion, cells were collected by 
centrifugation (471 x g for 5 minutes) and then cultured in DMEM, pH 7.4, with 10% heat-
inactivated FBS, 0.25% sodium pyruvate and 1% antibiotic/antimycotic. Cells were 
expanded until 3 passages and maintained under culture at 37
o
C with 5% CO2.  
 
4.2. Isolation and culture of mononuclear cells from peripheral blood samples 
A total of 8 healthy volunteers (4 male and 4 female with an average of 27.1 ± 6.5 years 
of age, ranging from 21 to 38 years of age) donated peripheral blood samples, which were 
collected, in heparin (Becton Dickinson Biosciences, San Jose, CA, USA), at the Blood 
and Transplantation Center of Coimbra (Coimbra, Portugal). All participants had 
previously given written informed consent regarding their participation in the study. 
Isolation of the peripheral blood mononuclear cells (PBMC) was carried out through 
Lymphoprep
TM
 (Axis-Shield Diagnotics, Oslo, Norway) gradient density centrifugation, 
within one hour of collection. Afterwards, the cells were washed twice in Hanks' balanced 
salt solution (HBSS) (Gibco) by 5 minutes centrifugation at 540 x g. The resulting PBMC 
pellet was resuspended in Roswell Park Memorial Institute (RPMI) 1640 with GlutaMax 
medium (Invitrogen, LifeTechnologies, Waltham, Massachusetts, USA) containing 0.1 % 
antibiotic-antimycotic (Gibco), to a final concentration of 10
6
 cells per mL. 
PBMC were then cultured in 24-well TPP tissue culture plates (TPP Techno Plastic 
Products AG, Zollstrasse, Trasadingen, Switzerland) and incubated, in a sterile 
environment, at 37
o
C, in a humidified atmosphere with 5% CO2, under the following 
experimental conditions: PBMC (10
6
 cells) in 1 mL of RPMI-1640 medium only (negative 
control); PBMC (10
6
 cells) in 1 mL RPMI-1640 medium with the addition of hAME to the 
culture medium (50, 100 or 200 μL); PBMC (106 cells) in 1 mL RPMI-1640 medium in 
co-culture with hAM-derived cells (either 0.5x10
6
 or 0.1x10
6
 cells, for a ratio PBMC-to-
hAM cells of 2:1 and 10:1, respectively). 
The incubation period was distinct for the different sets of experiments and is detailed 
below. 
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Figure 6. Basic scheme of the methodology adopted for the evaluation of the immunosuppressive 
potential of hAME and hAM-derived cells.  
 
4.3. Measurement of T lymphocyte proliferation 
PBMC differentiated under the abovementioned culture conditions, with or without 
addition of 200 μL of hAME to the cuture medium, were used for the assessment of cell 
proliferation after 5 days of culture (3 samples), with or without the addition of mitogen; 
either phytohemagglutinin (PHA), Staphylococcal protein-A (SPA) or pokeweed mitogen  
(PWM). Proliferation was evaluated through a thymidine incorporation assay, by adding 
[
3
H]-thymidine (0.67 Ci/well, Perkin Elmer, Life Sciences, Zaventem, Belgium) to the 
cells, and then allowing the cells to be labeled during 18 additional hours of incubation. 
Thymidine incorporation was measured following incubation, after harvesting the cells 
with a Filtermate Harvester (Perkin Elmer), with a microplate scintillation and 
luminescence counter (Top Count NXT, Perkin Elmer). 
Data were expressed as mean and standard deviation (SD), and differences between the 
two different cell cultures were considered significant when the p-value for the Wilcoxon 
signed-rank test for paired samples was lower than 0.05. 
 
Universidade de Aveiro                                                                                                    2015 
Marta Duque 45 
4.4. Flow cytometry analysis of immunophenotype 
T lymphocytes can be identified by their expression of CD3, T helper and T cytotoxic 
cells differ from each other in the expression of CD4 and CD8 (CD4
+
CD8
-
 and CD4
-
CD8
+
, 
respectively) and the naïve, memory and effector T cell subsets are phenotypically 
distinguished by the expression of isoforms of the CD45 antigen (or protein tyrosine 
phosphatase receptor type C), an important regulator of antigen receptor signaling in T and 
B lymphocytes. In the CD4
+
 and CD8
+
 T cell populations the CD45RA isoform is 
expressed by naïve and effector T cells (CD45RA
+
) but not by memory cells (CD45RA
-
), 
which, instead, express the CD45RO isoform. The difference arises because, after antigen 
experience, expression of CD45RA is lost while CD45RO expression takes its place 
(Mackay 1999). Central memory (TCM) and effector memory (TEM) T cells, in turn, can be 
distinguished by using one of several possible second markers, each associated to a slightly 
different stage of differentiation from the central to the effector memory phenotype. The 
chemokine receptor CCR7 is commonly used, as is the homing receptor CD26L, both of 
which are expressed by naïve T (CD45RA
+
CCR7
+
CD26L
+
) and TCM cells (CD45RA
-
CCR7
+
CD26L
+
). However, CCR7 is expressed at low levels and detection requires very 
bright antibody staining while CD26L expression is absent following certain protocols 
such as density gradient centrifugation, cryopreservation and T cell activation with phorbol 
myristate acetate (PMA) plus ionomycin. On the other hand CD27 and CD28, a tumor 
necrosis factor receptor and a co-stimulatory molecule, respectively, are expressed at 
higher levels by naïve T (CD45RA
+
CD27
+
CD28
+
) and TCM cells (CD45RA
-
CD27
+
CD28
+
) 
(Okada et al. 2008), but only one of those markers would be necessary to distinguish them, 
thus, for the purpose of identification of the different T cell subsets, the selected panel of 
markers was; CD3, CD4, CD8, CD45RA and CD27; naïve T cells were identified as 
CD45RA
+
CD27
+
 T cells, effector T cells as CD45RA
+
CD27
-
, TCM cells as CD45RA
-
CD27
+
 and TEM cells as CD45RA
-
CD27
-
. The panel also included the neural cell adhesion 
molecule CD56 to exclude NK cells (identified as CD3
-
CD56
+
 lymphocytes) (Table 9).  
The panel of markers selected for the characterization of hAM-derived cells included the 
profile suggested by the International Society of Cellular Therapy (Horwitz et al. 2005) for 
the identification of MSCs which other authors had reported to be applicable to hAM-
derived MSCs (Insausti et al. 2010, Lindenmair et al. 2012, Miki 2011); namely, HLA-DR, 
CD13, CD31, CD44, CD45, CD73 and CD90 (Table 9).  
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Table 9. Panel of mAb reagents (with clones and commercial sources) used for 
immunophenotypic characterization and fluorescence-activated cell sorting (FACS). 
  Fluorochrome 
  
PB V500  or      
KO 
FITC PE 
PECγ5 or 
PerCPCγ
5.5 
PECγ7 APC APCH7 
T
 c
el
ls
 
T
N
F
α
 /
 I
L
-1
7
 
CD3 
UCHT1 
BD 
Biosciences 
CD8 
RPA-T8 
BD 
Biosciences 
cyTNFα 
Mab11 
BD 
Biosciences 
cyIL-17 
SCPL1362 
BD 
Biosciences 
CD27 
1A4-CD27 
Beckman 
Coulter 
CD56 
N901 
Beckman 
Coulter 
CD45RA 
HI100 
BD 
Biosciences 
CD4 
SK3 
BD 
Biosciences 
IF
N
γ 
/ 
IL
-1
7
 
CD3 
UCHT1 
BD 
Biosciences 
CD8 
RPA-T8 
BD 
Biosciences 
cyIFNγ 
4S.B3 
BD 
Biosciences 
cyIL-17 
SCPL1362 
BD 
Biosciences 
CD27 
1A4-CD27 
Beckman 
Coulter 
CD56 
N901 
Beckman 
Coulter 
CD45RA 
HI100 
BD 
Biosciences 
CD4 
SK3 
BD 
Biosciences 
IL
-2
 /
 I
L
-1
7
 
CD3 
UCHT1 
BD 
Biosciences 
CD8 
RPA-T8 
BD 
Biosciences 
cyIL-2 
MQ-17H2 
BD 
Biosciences 
cyIL-17 
SCPL1362 
BD 
Biosciences 
CD27 
1A4-CD27 
Beckman 
Coulter 
CD56 
N901 
Beckman 
Coulter 
CD45RA 
HI100 
BD 
Biosciences 
CD4 
SK3 
BD 
Biosciences 
IL
-2
 /
 I
L
-9
 CD3 
UCHT1 
BD 
Biosciences 
CD8 
RPA-T8 
BD 
Biosciences 
cyIL-2 
MQ-17H2 
BD 
Biosciences 
cyIL-9 
MH9A3 
BD 
Biosciences 
CD27 
1A4-CD27 
Beckman 
Coulter 
CD56 
N901 
Beckman 
Coulter 
CD45RA 
HI100 
BD 
Biosciences 
CD4 
SK3 
BD 
Biosciences 
h
A
M
-e
ri
v
ed
 
ce
ll
s 
CD44 
Clone IM7 
Biolegend 
CD45 
J.33 
Beckman 
Coulter 
CD31 
WM59 
BD 
Pharmingen 
CD73 
AD2  
BD 
Pharmingen 
- CD13 
L138 
BD Bio-
sciences 
CD90 
5E10  
BD 
Pharmingen 
CD44 
Clone IM7 
Biolegend 
C
el
l 
S
o
rt
in
g
 
CD8 
RPA-T8 
BD 
Biosciences 
- CD25 
M-A251 
BD 
Biosciences 
CD127 
IM1980U 
Beckman 
Coulter 
CD4 
13B8.2 
BD Bio- 
sciences 
TCRγδ 
R9.12 
BD Bio-
sciences 
CD56 
IM2474 
Beckman 
Coulter 
CD3 
SK7 
BD 
Biosciences 
APC, allophycocyanin; APCH7, allophycocyanin-hilite 7; FITC, flurescein isothiocyanate; KO, khrome 
orange; mAb, monoclonal antibody; PB, pacific blue; PE, phycoerythrin; PECγ5, phycoerythrin-cyanine 5; 
PerCPCy5.5, peridinin chlorophyll protein-cyanine 5.5; PECγ7, phycoerythrin-cyanine 7; V500, Violet 500. 
Commercial Sources: BD Biosciences (Becton Dickinson Biosciences, San Jose, CA, USA); Beckman 
Coulter (Miami, Florida, USA); Biolegend (San Diego, CA, USA) 
 
Flow cytometry analysis of T cells and hAM-derived cells was performed in BD 
FACSCanto
TM
 II flow cytometer (BD Biosciences, Franklin Lakes, New Jersey, USA) and 
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data analysis was carried out through resort to the Infinicyt (version 1.6) software (Cytonos 
SL, Salamanca, Spain). 
 
4.4.1. Immunophenotypic study of peripheral blood T lymphocytes 
After 20 hours of PBMC incubation with hAME or hAME-derived cells (8 samples), the 
stimulants PMA (1 ng/mL, Sigma-Aldrich) and ionomycin (0.5 mg/mL, Sigma-Aldrich) 
were added to the wells, along with brefeldin A (5 mg/mL, Sigma-Aldrich) to prevent the 
release of de novo produced cytokines. The plates were then incubated for 4 more hours, in 
a sterile environment, at 37
o
C, in a humidified atmosphere with 5% CO2, after which 
analysis was performed by flow cytometry. 
Prior to cell staining, the cells were concentrated, by 5 minutes of centrifugation at 540 x 
g, and the supernatants discarded. All cells were stained with the same monoclonal 
antibodies (mAb) for surface proteins antigens CD3, CD4, CD8, CD56, CD27 and 
CD45RA (Table 9). The subsequent permeabilization step was performed with the 
permeabilization kit Intraprep™ (Beckman Coulter, Brea, California, USA) according to 
manufacturer instructions: after 10 minutes of incubation in the dark at RT, with the mAb, 
cells were washed in PBS (5 minutes at 540 x g) and treated with fixing solution for 10 
more minutes in the dark at RT. Cells were then washed one more time with PBS (5 
minutes at 540 x g) and the supernatants discarded. Lysis and permeabilization solution 
was applied for lysis of red blood cells and permeabilization of the leukocytes’ 
membranes. Cells were subsequently stained with the mAb for intracellular TNFα along 
with IL-17, IFNγ with IL-17, IL-2 with IL-17, or IL-2 with IL-9 (combinations depicted in 
Table 9). After 10 minutes of incubation in the dark at RT, samples were washed twice 
with PBS (5 minutes at 540 x g); the cell pellet was resuspended in 250 μL PBS and 
immediately acquired.  
As previously mentioned, the subpopulations of CD4
+
 and CD8
+
 T cells (phenotypically 
characterized as CD3
+
CD4
+
CD8
-
 and CD3
+
CD4
-
CD8
+
, respectively) were identified as 
falling into the naïve, effector, central memory and effector memory functional 
compartments according to their expression profile of the surface markers CD45RA and 
CD27, as follows; CD45RA
+
CD27
+
 were identified as being naïve T cells, CD45RA
-
CD27
+
 as TCM cells, CD45RA
-
CD27
-
 expression was attributed to TEM cells and 
CD45RA
+
CD27
-
 to effector T cells. 
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Data were expressed as mean ± SD and differences between different culture conditions 
were considered significant when the p-value for the Wilcoxon signed-rank test for paired 
samples was lower than 0.05. 
 
4.4.2. Immunophenotypic characterization of hAM-derived cells 
The hAM-derived cells, from 4 different samples, were concentrated (5 minutes at 540 x 
g) and the supernatants discarded. Cells were then labeled with the mAb for surface 
markers HLA-DR, CD13, CD31, CD44, CD45, CD73 and CD90 (Table 9) in a 10 minutes 
incubation, in the dark at RT. Cells were then washed with PBS (5 minutes at 540 x g), the 
cell pellet was resuspended in 250 μL PBS and immediately acquired.  
Differences between identified cell populations were considered significant when the p-
value for the Mann-Whitney test was lower than 0.05. 
 
4.5. Purification of T cell subtypes by fluorescence-activated cell-sorting 
Using a 7-color mAb combination (depicted in Table 9), the CD4
+
 and CD8
+
 T cells in 
culture (from 5 samples) were purified by fluorescence-activated cell-sorting (FACS) 
according to their characteristic phenotype, using a FACSAria
TM
 II flow cytometer (BD 
Biosciences). 
The cells were concentrated by 5 minutes of centrifugation at 540 x g and the 
supernatants were discarded. Subsequently, cells were stained with the mAb for surface 
proteins antigens CD8, CD25, CD127, CD4, CD56, CD3 and TCRγδ (Table 9). CD4+ T 
cells were identified as CD3
+
CD4
+
CD8
-
 and CD8
+
 T cells as CD3
+
CD4
-
CD8
+
, the 
remainder immunophenotypic markers were used to identify regulatory T cells 
(CD25
+
CD127
+) and γδ T cells (CD3+TCRγδ+). The purified T cell populations were 
subsequently used for the relative quantification of mRNA expression. 
 
4.6. Relative mRNA expression by purified CD4
+
, CD8
+
, regulatory and gamma-
delta T cells. 
Purified T cell populations were transferred to a 1.5 mL eppendorf tube, centrifuged 5 
minutes at 300 x g and the pellet resuspended in 350 μL of RNeasy Lysis Buffer (RTL, 
Qiagen, Hilden, Germany). Total RNA was extracted with the RNeasy Micro kit (Qiagen), 
according to supplier’s instructions. Total RNA was eluted onto a 20 μL volume of RNase-
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free water. Reverse transcription was then performed with iScript
TM
 Reverse Transcription 
Supermix for RT-PCR (Bio-Rad, Hercules, California, USA), according to manufacturer’s 
instructions. Relative quantification of gene expression by real-time polymerase chain 
reaction (RT-PCR) was performed in the LightCycler
TM
 480 II (Roche Diagnostics, 
Rotkreuz, Switzerland). RT-PCR reactions were performed using 1xQuantiTect SYBR 
Green PCR Master Mix (Qiagen), 1xQuantiTect Primer Assay (GATA3: QT00095501; 
STAT6: QT00097426; IL-4: QT00012565; FOXP3: QT00048286; IL-10: QT00041685; 
TGFβ1: QT00000728; PRF1: QT00199955; GZMB: QT01004875; KLRK1: QT00197183; 
EOMES: QT00026495) (Qiagen), in a final volume of 10 μL. The reactions were 
performed using the following thermal profile: 15 minutes at 95
o
C, 50 cycles of 15 seconds 
at 94
o
C, 30 seconds at 55
o
C and 30 seconds at 72
o
C, 1 cycle of 15 seconds at 95
o
C, 15 
seconds at 60
o
C and continuo at 95
o
C and 1 cycle of 30 seconds at 37
o
C. All samples were 
run in duplicate and melting point analysis was done to ensure the amplification of the 
desired product. RT-PCR results were analyzed with the LightCycler
TM
 software (Roche 
Diagnostics). 
Two reference genes for data normalization were selected using the GeNorm software 
(PrimerDesign Ltd., Southampton, England), for all T cell populations the more stable 
reference genes were; cytochrome c1 (CYC1) and splicing factor 3a subunit 1 (SF3A1). 
The normalized expression levels of the genes of interest were calculated using the delta-
Ct method. 
Relative mRNA expression data was expressed through their quartiles with non-
parametric box-plots. Differences between the two culture conditions were considered 
significant when the p-value for the Wilcoxon paired-sample test was lower than 0.05.  
 
4.7. Statistical analysis 
Statistical analysis was performed by the non-parametric Wilcoxon paired-sample test or 
Mann-Whitney Test. Statistical significance was considered when p-value was lower than 
0.05 (significance level of 5%). The data analysis was generated using the Real Statistics 
Resource Pack software (Release 3.8) (Copyright 2013 – 2015, Charles Zaiontz).  
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5. RESUTS 
 
5.1. hAM-derived cells characterization 
The cells isolated from hAM had demonstrated plastic culture adherence and reached 80 
to 90% confluence (proportion of plastic surface covered) after a few days of culture. The 
cellular population was easily expanded in vitro until 3 passages without any visible 
morphological alterations. Two types of cells were present in the total population: the 
epithelial cells, with a polygonal morphology and an irregular, large and homogeneous 
nucleus, and the mesenchymal cells, with typical fusiform/fibroblast-like morphology. The 
hAM-derived cells used in all co-culture experiments had a maximum of 2 passages. 
 
 
 
Figure 7. Phenotypic characterization of hAM-derived cells. Left panel: Bivariate dot plot 
histogram illustrating the hAM-derived cells, following culture, displaying two distinct cell 
populations; A and B. Right panel: Phenotypic characterization of the two cell populations 
identified in hAM-derived cell cultures as the expression level of several phenotypic markers, 
measured as the mean fluorescence intensity (MFI) (mean ± SD). Results were obtained with four 
hAM samples. Statistically significant differences were considered when p<0.05 for the Mann-
Whitney Test: * for the groups indicated in the figure. 
 
The phenotypic characterization of 4 samples of hAM-derived cells revealed two major 
cell populations (Figure 7), one more abundant than the other (98.2% ± 1.3% and 1.8% ± 
1.3%, respectively), which differed from each other, mainly, in the expression of the 
phenotypic markers CD73, CD13, CD90 and CD44, with the scarcer population having a 
significantly higher expression level for all aforementioned markers, particularly CD90 
(CD73
+
CD13
+
CD44
+
CD90
high
). 
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5.2. Evaluation of the anti-proliferative effect of hAME  
The presence of hAME in the culture medium did not cause significant changes in basal 
cell proliferation in the absence of mitogenic stimulation, but, there was a decrease in [H
3
]-
thymidine incorporation when PBMC were activated with either PHA or PWM (Figure 8). 
Additionally, in the cases where hAME produced an inhibitory effect, there was no 
significant difference between 50 μL, 100 μL and 200 μL of hAME.  
These results demonstrate that hAME can inhibit lymphocyte proliferation induced by 
mitogenic stimuli. 
 
 
 
Figure 8. Thymidine incorporation assay. Results represent PBMC proliferation, measured as 
[H
3
]-thymidine incorporation (mean ± SD) without mitogen stimulation or following PBMC 
activation by mitogenic stimuli. Results were obtained for three PBMC samples. Statistically 
significant differences were considered when p<0.05 for the Wilcoxon paired-sample test: * for the 
groups indicated in the figure. 
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5.3. Influence of the dosage over hAME-mediated anti-inflammatory effects 
PBMC culture with hAME resulted in a decrease of the frequency of T cells expressing 
TNFα, following stimulation with PMA plus ionomycin (Figure 9).  
 
 
 
Figure 9. Effect of different doses of hAME over the frequency of TNFα-expressing CD4+ and 
CD8
+
 T cells. (A-B) Percentage of TNFα-producing CD4+ (A) and CD8+ T cells (B) (mean ± SD) 
among four different subsets (naïve, central memory, effector memory and effector) following 
PBMC stimulation in the absence (PBMC+PMA+Ionomycin) or presence of hAME in the culture 
medium (PBMC+50μL hAME+PMA+Ionomycin, PBMC+100μL hAME+PMA+Ionomycin, 
PBMC+200μL hAME+PMA+Ionomycin). (C-D) Percent inhibition (mean ± SD) induced by 
hAME on the frequency of TNFα producing CD4+ (C) and CD8+ T cells (D). Results were obtained 
for three PBMC samples. Statistically significant differences were considered when p<0.05 for the 
Wilcoxon paired-sample test: * versus PBMC+PMA+Ionomycin; ** for the groups indicated in the 
figure. 
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Unlike the observed inhibitory effect over cell proliferation, this effect was dependent on 
the amount of hAME added to the culture medium, in most cases only being significant for 
the highest dose of hAME. 
Additionally, CD4
+
 and CD8
+
 T cells, and the different T cell subsets amongst them, 
displayed different susceptibility to inhibition. For instance, the decrease in the frequency 
of total CD4
+TNFα+ T cells was more pronounced than that of total CD8+TNFα+ T cells. 
The effector subsets, among both CD4
+TNFα+ and CD8+TNFα+ T cells, were only affected 
by the highest dose of hAME, on the other hand, TCM cells seemed the most susceptible to 
the inhibitory effect of hAME, being the only subset among CD4
+TNFα+ and CD8+TNFα+ 
T cells which was affected by the lowest dose of hAME. 
Thus, hAME decreases the frequency of TNFα producing T cells, in a dose-dependent 
manner, with different susceptibility to inhibition among different T cell subsets. 
In all subsequent experiments only the highest dose of hAME (200 μL) was added the 
culture medium. 
 
5.4. Frequency of TNFα, IFNγ and IL-2 producing T cells 
The addition of hAME to the PMA+Ionomycin-stimulated PBMC culture medium 
decreased the frequency of CD4
+
 and CD8
+
 TNFα, IFNγ and IL-2 expressing T cells, with 
different susceptibility to inhibition among different T cell subsets. 
The presence of hAME reduced the percentage of CD8
+TNFα+ T cells and CD4+TNFα+ T 
cells among all T cell subsets and, as previously observed, the overall inhibitory effect was 
more preeminent among CD4
+
 T cells comparatively with CD8
+
 T cells (Figure 10). The 
difference arose mainly from a more pronounced effect over CD4
+TNFα+ TCM cells, 
comparatively to CD8
+TNFα+ TCM cells, while no significant differences were observed 
between the two groups among the other subsets. 
Regarding IFNγ+ T cells, the frequency of cytokine producing cells was significantly 
reduced in nearly all T cell subsets, with the exception of CD8
+IFNγ+ effector T cells 
(Figure 11). Once again the overall inhibition appears to be greater for CD4
+
 T cells in 
comparison with CD8
+
 T cells. The same discrepancy was not observed among IL-2
+
 T 
cells; in this case, there was a decrease of IL-2 producing cells in all T cell subsets without 
major differences between CD4
+
IL-2
+
 and CD8
+
IL-2
+
 T cells, or between different T cell 
subsets (Figure 12).  
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Figure 10. Effect of hAME over TNFα expressing CD4+ and CD8+ T cells. (A-B) Percentage of 
TNFα producing CD4+ (A) and CD8+ T cells (B) (mean ± SD), distributed among the naïve, central 
memory, effector memory and effector subsets, following PBMC stimulation in the absence 
(PBMC+PMA+Ionomycin) or presence of hAME in the culture medium (PBMC+200μL 
hAME+PMA+Ionomycin). (C-D) Amount of TNFα expressed per CD4+ (C) and CD8+ T cell (D), 
measured as the MFI (mean ± SD). (E-F) Percent inhibition (mean ± SD) induced by hAME on the 
frequency of TNFα producing CD4+ and CD8+ T cells (E) and amount of TNFα expressed per cell 
(F). Results were obtained for eight PBMC samples. Statistically significant differences were 
considered when p<0.05 for the Wilcoxon paired-sample test: * versus PBMC+PMA+Ionomycin; 
** for the groups indicated in the figure. 
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Figure 11. Effect of hAME over IFNγ expressing CD4+ and CD8+ T cells. (A-B) Percentage of 
IFNγ producing CD4+ (A) and CD8+ T cells (B) (mean ± SD), distributed among the naïve, central 
memory, effector memory and effector subsets, following PBMC stimulation in the absence 
(PBMC+PMA+Ionomycin) or presence of hAME in the culture medium (PBMC+200μL 
hAME+PMA+Ionomycin). (C-D) Amount of IFNγ expressed per CD4+ (C) and CD8+ T cell (D), 
measured as the MFI (mean ± SD). (E-F) Percent inhibition (mean ± SD) induced by hAME on the 
frequency of IFNγ producing CD4+ and CD8+ T cells (E) and amount of IFNγ expressed per cell 
(F). Results were obtained for eight PBMC samples. Statistically significant differences were 
considered when p<0.05 for the Wilcoxon paired-sample test: * versus PBMC+PMA+Ionomycin; 
** for the groups indicated in the figure. 
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Figure 12. Effect of hAME over IL-2 expressing CD4
+
 and CD8
+
 T cells. (A-B) Percentage of 
IL-2 producing CD4
+
 (A) and CD8
+
 T cells (B) (mean ± SD), distributed among the naïve, central 
memory, effector memory and effector subsets, following PBMC stimulation in the absence 
(PBMC+PMA+Ionomycin) or presence of hAME in the culture medium (PBMC+200μL 
hAME+PMA+Ionomycin). (C-D) Amount of IL-2 expressed per CD4
+
 (C) and CD8
+
 T cell (D), 
measured as the MFI (mean ± SD). (E-F) Percent inhibition (mean ± SD) induced by hAME on the 
frequency of IL-2 producing CD4
+
 and CD8
+
 T cells (E) and amount of IL-2 expressed per cell (F). 
Results were obtained for eight PBMC samples. Statistically significant differences were 
considered when p<0.05 for the Wilcoxon paired-sample test: * versus PBMC+PMA+Ionomycin; 
** for the groups indicated in the figure. 
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The inhibitory effect of hAME over the frequency of cytokine producing cells seemed to 
differ not only between CD4
+
 and CD8
+
 T cells, and between different subsets, but also 
according to the cytokine under study. Interestingly, among CD4
+TNFα+ T cells, the naïve 
T cells were less significantly affected than CD4
+TNFα+ TCM or TEM cells (CD4
+TNFα+ 
TCM cells seemingly being more strongly inhibited than the rest), while the opposite result 
was observed for CD4
+IFNγ+ naïve T cells, which yielded greater percent inhibition than 
CD4
+IFNγ+ TCM or TEM cells. On the other hand, there was no major difference in the 
effect over the frequency of IL-2
+
 T cells between different T cell populations. 
In addition to the clear reduction in the frequency of cytokine producing cells, there was 
also a slight decrease in the quantity of cytokine produced per cell, expressed by the 
diminishing mean fluorescence intensity (MFI), in most CD4
+
 and CD8
+
 T cell subsets, the 
exceptions being CD4
+TNFα+ naïve, CD8+TNFα+ effector, CD4+IFNγ+ TEM, CD8
+IFNγ+ 
TEM, CD4
+IFNγ+ effector and CD8+IFNγ+ effector T cells (Figures 10-12). However, the 
decrease in MFI, albeit consistent throughout the data, is much less pronounced than the 
reduction of cytokine producing cells: in the presence of hAME there was an overall 
decrease in the frequency of TNFα+ T cells in 56% and 37% (for CD4+ and CD8+ T cells, 
respectively), while the TNFα-MFI decreased only in 5% and 4%. Similarly, the overall 
frequencies of IFNγ+ and IL-2+ T cells decreased in 43% and 31% (for CD4+IFNγ+ and 
CD8
+IFNγ+ T cells), and 55% and 60% (for CD4+IL-2+ and CD8+IL-2+ T cells) while the 
respective percent inhibition of MFI was 8% (for both CD4
+IFNγ+ and CD8+IFNγ+ T 
cells), and 4% and 8% (for CD4
+
IL-2
+
 and CD8
+
IL-2
+
 T cells). 
 
5.5. Frequency of IL-17 and IL-9 producing T cells 
CD4
+
 and CD8
+
 T cells activated in the presence of hAME also displayed lower 
frequencies of IL-9 and IL-17 producing cells, in comparison with the negative controls. 
However, for both cytokines under study, no significant difference was observed between 
CD4
+
 and CD8
+
 T cells (Figures 13 and 14).  
The hAME also decreased the frequency of CD4
+
 and CD8
+
 T cells that simultaneously 
express IL-9 and IL-2 (Figure 13), and IL-17 with TNFα, IFNγ or IL-2 (Figure 14). 
Although, in the case of IL-17
+IFNγ+ T cells, there was only a significant decrease in 
percentage among CD4
+
 T cells and not within CD8
+
 T cells (Figure 14).  
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Figure 13. Effect of hAME over IL-9
+
 and IL-9
+
IL-2
+
 T cells. (A) Percentage of IL-9 producing 
cells (mean ± SD), within total CD4
+
 and CD8
+
 T cells, following PBMC stimulation in the 
absence (PBMC+PMA+Ionomycin) or presence of hAME in the culture medium (PBMC+200μL 
hAME+PMA+Ionomycin). (B) Percentage of IL-9 producing T cells that simultaneously express 
IL-2 (mean ± SD). (C-D) Amount of protein expressed per cell among IL-9
+
 (C) and IL-9
+
IL-2
+
 T 
cells (D) (MFI, mean ± SD). (E-F) Percent inhibition (mean ± SD) induced by hAME over the 
frequency of IL-9
+
 and IL-9
+
IL-2
+
 T cells (E) and amount of cytokine expressed per cell (F). 
Results were obtained for eight PBMC samples. Statistically significant differences were 
considered when p<0.05 for the Wilcoxon paired-sample test: * versus PBMC+PMA+Ionomycin; 
** for the groups indicated in the figure. 
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Figure 14. Effect of hAME over IL-17
+
, IL-17
+TNFα+, IL-17+IFNγ+ and IL-17+IL-2+ T cells. (A) 
Percentage of IL-17 producing cells (mean ± SD), within total CD4
+
 and CD8
+
 T cells following 
PBMC stimulation the absence (PBMC+PMA+Ionomycin) or presence of hAME in the culture 
medium (PBMC+200μL hAME+PMA+Ionomycin). (B-D) Percentage of IL-17 producing CD4+ 
and CD8
+
 T cells that simultaneously express TNFα (B), IFNγ (C) or IL-2 (D). (E-H) Amount of 
protein expressed per cell among IL-17
+
 (E), IL-17
+TNFα+ (F), IL-17+IFNγ+ (G) and IL-17+IL-2+ T 
cells (H) (MFI, mean ± SD). (I-J) Percent inhibition (mean ± SD) induced by hAME on the 
frequency of IL-17
+
, IL-17
+TNFα+, IL-17+IFNγ+ and IL-17+IL-2+ T cells (I) and amount of 
cytokine expressed per cell (J).  Results were obtained for eight PBMC samples. Statistically 
significant differences were considered when p<0.05 for the Wilcoxon paired-sample test: * versus 
PBMC+PMA+Ionomycin; ** for the groups indicated in the figure. 
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Moreover the presence of hAME also produced a minor reduction in the amount of 
cytokine produced per cell (Figures 13 and 14), but this decrease was much less 
pronounced than the decrease in the frequency of cytokine producing cells; hAME reduced 
the percentage of IL-9
+
 and IL-17
+
 T cells in 44% and 41% (for CD4
+
IL-9
+
 and CD8
+
IL-
9
+
, respectively), and 40% and 31% (for CD4
+
IL-17
+
 and CD8
+
IL-17
+
, respectively) while 
the decrease in MFI was substantially smaller; namely, of 5% and 7% (for CD4
+
IL-9
+
 and 
CD8
+
IL-9
+
, respectively), and 5% and 3%  (for CD4
+
IL-17
+
 and CD8
+
IL-17
+
, 
respectively). 
The decrease in the frequency of cells that express two cytokines at the same time was 
also accompanied by a small decrease in the amount of each cytokine produced per cell, 
with the exception of IL-17
+IFNγ+ T cells (CD4+ and CD8+) and for the MFI of IL-17 in 
IL-17
+TNFα+ and IL-17+IL-2+ CD8+ T cells (Figures 13 and 14). 
 
 
 
Figure 15. Effect of hAM-derived cells over the frequency of IL-2 expressing T cells. Percentage 
of IL-2 producing cells among different CD4
+
 (A) and CD8
+
 T cell (B) subsets (naïve, central 
memory, effector memory and effector) (mean ± SD) following PBMC stimulation in the absence 
(PBMC+PMA+Ionomycin) or presence of hAM-derived cells, in a proportion of PBMC-to-hAM-
derived cells of either 10:1 (PBMC+10:1 hAM cells+PMA+Ionomycin) or 2:1 (PBMC+2:1 hAM 
cells+PMA+Ionomycin), in the culture medium. Results were obtained for two PBMC samples and 
two replicates. Statistically significant differences were considered when p<0.05 for the Wilcoxon 
paired-sample test: * versus PBMC+PMA+Ionomycin. 
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Conversely, co-culture of PBMC with hAM-derived cells, at a ratio of PBMC to hAM-
derived cells of 10:1 or 2:1, did not produce the same effects; the presence of hAM-derived 
cells did not significantly reduced the frequency of TNFα+, IFNγ+, IL-17+ or IL-9+ T cells 
(data not shown). Interestingly there was a significant reduction in the overall percentage 
of CD4
+
IL-2
+
 and CD8
+
IL-2
+
 T cells (Figure 15), but, among the different T cell subsets, 
only TCM cells (CD4
+
 and CD8
+
) were affected, which is not surprising considering that the 
previous results, with hAME, pointed to IL-2
+
 TCM cells possibly being the more 
susceptible to inhibition of all the analyzed cytokine producing cell populations. 
 
5.6. mRNA expression in purified T cell populations  
Different T cell subsets were isolated from the cultures in the presence or absence of 
hAME; namely, CD4
+
 T cells, CD8
+
 T cells, Treg cells and γδ T cells. The sorted subsets 
were then analyzed for mRNA expression and the results, like the results from the T cell 
proliferation assay and quantification of pro-inflammatory cytokine production, 
demonstrated that hAME exerted a general anti-inflammatory effect over T lymphocytes, 
by suppressing ‘aggressive’ T cell phenotypes and promoting and/or inducing suppressor 
phenotypes among Treg cells and CD4
+
 T cells. 
Flow cytometry results revealed a decrease, among CD4
+
 T cell subpopulation, in the 
overall production of pro-inflammatory cytokines typically associated with Th1 cells, 
when PBMC were cultured in the presence of hAME. Under the same conditions, mRNA 
expression revealed a decrease in mRNA expression of the Th2-associated transcription 
factors GATA3 and STAT6, and in the mRNA expression of the Th2-related cytokine IL-
4. Simultaneously, there was an increase in Foxp3 and IL-10 mRNA expression (Figure 
16). Taken together, these results suggest that hAME skews Th cell polarizat ion ‘away’ 
from the Th1 and Th2 phenotypes and towards induced regulatory phenotypes (which 
express Foxp3 and secrete anti-inflammatory cytokines) such as Tr1 or Th3. 
The overall anti-inflammatory effect of hAME is also observed among CD8
+
 and γδ T 
lymphocytes. These cell populations demonstrated a decrease in the mRNA expression of 
the cytolytic protein perforin 1, apoptosis-inducing protein granzime B and activating 
receptor NKG2D (Figure 16). These results point to a hAME-mediated reduction in T cell 
activation and cytotoxicity. Additionally, whithin γδ T cells, there was a reduction in the 
mRNA expression of eomesodermin (EOMES). 
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Figure 16. mRNA expression in purified CD4
+
, CD8
+, γδ T and Treg cells. Semi-quantitative 
analysis of mRNA expression in FACS-purified T cells from two separate culture conditions: 
PBMC stimulated in the absence (PBMC+PMA+Ion; blue bars) or presence of hAME 
(PBMC+200μL hAME+PMA+Ion; orange bars). Results were obtained for five PBMC samples. 
Statistically significant differences were considered when p<0.05 for the Wilcoxon paired-sample 
test: * for the groups indicated in the figure. 
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Finally, among the purified Treg cell population, the presence of hAME in the culture 
medium resulted in augmented IL-10 mRNA expression and diminished TGFβ1 mRNA 
expression, even though both IL-10 and TGFβ are cytokines with by and large anti-
inflammatory roles. The Foxp3 mRNA levels, however, remained unchanged despite the 
presence of hAME (Figure 16). 
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6. DISCUSSION 
 
The inhibitory effect of hAM and hAM-derived MSCs over T cell proliferation and T 
cell-mediated immune responses has already been documented for T cells in general and, 
more recently, for different T helper effector cell populations (mostly Th1, Th2 and Th17), 
but data regarding the concrete effects over individual T cell subsets is very limited, as is 
information concerning the ‘unconventional’ T cell subpopulations, such as γδ T cells, and 
also Th cell subsets other than the more well known types 1, 2 and 17; for instance, Th9, 
Th3 and Tr1 cells. This data would be important for understanding, in greater detail, the 
effect of these cells on immune responses in vivo, given that they result from a composite 
network of different cell populations. 
The objective of this study was, therefore, to evaluate the influence of a hAM extract over 
T cell-mediated responses, focusing on the particular effects over individual T cell 
subpopulations (CD4
+
, CD8
+, Treg and γδ T cells) and different CD4+ and CD8+ T cell 
subsets (naïve, central memory, effector memory and effector) from the peripheral blood of 
healthy blood donors. In general, the hAME displayed an immunosuppressive effect over T 
cell proliferation, pro-inflammatory cytokine production and mRNA expression among the 
studied T cell populations. 
Morphological and flow cytometry analyses showed that the hAM-derived cells, from 
which the hAME was obtained, included of two distinct cell populations; one, more 
abundant, morphologically similar to amniotic epithelial cells (98.2% ± 1.3%) and a 
minority population of cells, which resembled mesenchymal stromal cells (1.8% ± 1.3%). 
Both cell populations lacked expression for the endothelial marker CD31, the 
hematopoietic marker CD45 and for MHC class II molecule HLA-DR. hAM cells have 
been shown to express HLA-A, -B and –C surface antigens but not HLA-DR (Hu et al. 
2009), while MSCs can express HLA-DR, under certain conditions, but are usually 
distinguished as being HLA-DR negative (Dominici et al. 2006).  
The two distinct cell populations differed from one another in the expression levels for 
the panel of mesenchymal stromal cell markers; CD73, CD13, CD90 and CD44. The more 
abundant cell population was negative for all four aforementioned markers, and, thus, 
likely corresponds to epithelial amniotic cells. The other, scarcer population displayed an 
expression profile similar to that of MSCs, according to the International Society for 
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Cellular Therapy (Dominici et al. 2006), namely; positive staining for CD13, CD73 and 
CD90 and for the adhesion molecule CD44, along with the lack of CD45 expression. The 
relatively high expression of CD90 displayed by this cell population deserves particular 
attention since, in human MSCs; the CD90
high
 phenotype is correlated with a stronger 
ability to suppress T cell proliferation, while low CD90 positivity correlates with loss of 
inhibitory ability (Campioni et al. 2009). The presence of this cell population within hAM 
has led other investigators to speculate whether the immunomodulatory activities of MSCs 
have an appreciable role in maternal-fetal immune tolerance, but the hypothesis is yet to be 
proven (Magatti et al. 2008). 
Either one of the two cell populations (or possibly both), found in the hAM-derived cell 
samples  might be the source of the immunossupressive factors present in the hAME, since 
both hAM epithelial cells and hAM-derived MSCs possess the ability to suppress T cell 
proliferation and activation. 
By culturing human peripheral blood mononuclear cells in the presence of hAME the first 
observation was of an anti-proliferative effect over mitogen-activated cells, which seemed 
to be independent from the dose of hAME, a curious result considering that, in most other 
studies, the inhibitory effect of hAM-derived MSCs (and conditioned medium) (Alikarami 
et al. 2015, Castro-Manrreza & Montesinos 2015, Insauti et al. 2014, Kang et al. 2012, 
Magatti et al. 2008, Prokop & Oh 2012, Yang et al. 2009,) or  hAM (and conditioned 
medium) (Insausti et al. 2014, Liu et al. 2012, Magatti et al. 2008, McDonald et al. 2015, 
Miki 2011, Rossi et al. 2012) is dose-dependent. 
Inhibition of T lymphocyte proliferation mediated by hAM cells (Magatti et al. 2008, 
McDonald et al. 2015, Ueta et al. 2002), or conditioned medium from hAM cells (Rossi et 
al. 2012), has already been reported for cell proliferation induced by allogeneic target cells 
or through T-cell receptor engagement, but not for mitogen-induced T cell proliferation, 
except for concanavalin A-activated mouse splenocytes (Liu et al. 2012). This anti-
proliferative effect is thought to involve prostaglandins as key effector molecules (Rossi et 
al. 2012). Moreover, amniotic epithelial cells produce soluble HLA-G (particularly HLA-
G5) (Kubo et al. 2001) that can inhibit T cell proliferation through the suppression of cell 
cycle progression (Bahri et al. 2006). 
 hAM-derived MSCs, on the other hand, are known to be able to suppress CD4
+
 and 
CD8
+
 T cell proliferation induced by several stimuli, including alloantigens and mitogen 
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stimulation (Lindenmair et al. 2012, Pianta et al. 2015), likely through the release of a 
variety of mediators, particularly prostaglandin E2 (PGE2) and indoleamine 2,3-
dioxygenase (IDO). 
The differentiation of T lymphocytes into memory and effector T cells is a crucial event 
in adaptive immune responses, thus, the effect of hAME over the individual naïve, central 
memory, effector memory and effector T cell responses was characterized through the 
identification of the different T cell subsets and evaluation of the frequency of pro-
inflammatory cytokine producing cells through flow cytometry. The results showed a 
relatively strong inhibition (between 30-60%) of the frequency of CD4
+
 and CD8
+
 T cells 
that produce pro-inflamatory cytokines (TNFα, IFNγ, IL-2, IL-17 and IL-9), following 
activation with PMA plus ionomycin. The extent of that inhibition differed not only 
between CD4
+
 and CD8
+
 T cells, and between different subsets, but also according to the 
cytokine under study. For instance, the relative susceptibility to inhibition of naïve T cells 
varied greatly depending on the cytokine in question; among CD4
+TNFα+ T cells, the 
naïve cells were less significantly affected than CD4
+
 TCM or TEM cells (CD4
+
 TCM cells 
seemingly being more strongly inhibited than the rest), while the opposite was observed for 
naïve CD4
+IFNγ+ T cells, which yielded greater percent inhibition than CD4+ TCM or TEM 
cells. On the other hand, there was no difference in the effect over the frequency of IL-2
+
 T 
cells between the four different subsets. Still, the results obtained for TNFα+ and IFNγ+ 
point to a differential regulation of each individual T cell subpopulation. As a result, the 
specific immunomodulatory action of hAME over a given immune response will be 
dependent on the cellular context. 
Overall, the T cell subset most susceptible to hAME-mediated immunosuppression 
seemed to be the TCM cells, and the most susceptible types of cytokine producing cells 
were the IL-2
+
 T cells, the only group where all subsets were strongly affected and in equal 
measure. This marked decrease in IL-2 expression among all T cell subsets may aid in the 
abovemenioned anti-proliferative effect of hAME, given the role of IL-2 in the induction 
of proliferation in resting T cell (Liao et al. 2011). 
The other pro-inflammatory cytokines under study were IL-17 and IL-9 and, as before, 
the presence of hAME decreased the overall frequency of CD4
+
 and CD8
+
 T cells that 
produced IL-17 and IL-9. Additionally, the presence of hAME also reduced the overall 
frequency multifunctional CD4
+
 and CD8
+
 T cells; namely, T cells that simultaneously 
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produce TNFα together with IL-17, IL-2 with IL-17, IL-2 with IL-9, and also IL-
17
+IFNγ+CD4+ T cells (the IL-17+IFNγ+CD8+ T cells being unaffected). Once again, the 
extent of the inhibition varied according the cytokine under study; the highest percent 
inhibition was observed for the cells that produced IL-2 (IL-17
+
IL-2
+
 and IL-9
+
IL-2
+
 T 
cells) and the lowest for IL-17
+IFNγ+ T cells. 
Within the CD4
+
 T cell population, the decrease in frequency of Th17-related (IL-17), 
Th9-related (IL-9), and Th1-related (TNFα, IFNγ and IL-2) cytokine producing cells points 
to an inhibition of Th17, Th9 and Th1 subsets. Also within this population there was a 
decrease in the mRNA expression of the Th-2-associated markers GATA-3, STAT6 and 
IL-4, suggesting a downregulation of the Th2 subset, and an increase in Foxp3 and IL-10 
mRNA expression, indicating an induction of regulatory T cells. Although, while hAME 
seems to directly influence Th2 polarization in a negative manner, there may be an indirect 
skewing towards type 2 Th cells due to the reduction of IFNγ and increased IL-10 (Murphy 
et al. 2013). 
The general effect of hAME over the CD4
+
 T cell population seems to be the induction of  
regulatory phenotypes, such as Tr1 (characterized by high IL-10 secretion), at the cost of 
the inflammatory effector Th subsets. 
The hAM has been reported by previous studies to suppress the production type 1 and 
type 2 cytokines by T cells, in contact-independent manner; Ueta et al. (2002) observed the 
inhibition of alloreactive synthesis of IL-2, IFNγ and IL-6 when murine mixed lymphocyte 
reactions were separated from hAM in by a permeable membrane, however, the group 
failed to detect the known inhibitory hAM-derived cytokines IL-4, IL-10 and TGFβ in the 
culture supernatant. The therapeutic benefit of this hAM-mediated reduction in cytokine 
production was demonstrated by Bauer and collegues’ study (2009), wherein it was 
reported a decrease in IFNγ and IL-2 production following culture of lymphocytes, from 
herpes simplex virus (HSV)-1–infected mice, in the presence of hAM. In the same study, 
treatment of murine corneas with herpetic stromal keratitis with hAM transplantation also 
resulted in a decrease in IL-2 production (Bauer et al.2009). 
However, the two aforementioned studies reported a decrease in the production of IL-10, 
while, in this case, the presence of hAME in the cultures of PBMC upregulated IL-10 
mRNA expression among Treg and CD4
+
 T cells. Similarly, MacDonald’s group (2015) 
observed a significant reduction of IFNγ and TNFα, as well as IL-10, by activated T cells 
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in the presence of hAM epithelial cells, but the group also reported that there was no 
change in the production of IL-4 or IL-17A in vitro, although, in vivo, the administration 
these hAM epithelial cells in an experimental autoimmune encephalomyelitis mouse model 
decreased IL-17A and increased IL-4 secretion, and resulted in polarization towards a 
regulatory phenotype, leading to increased numbers of CD4
+
CD25
+
Foxp3
+
 Treg cells. This 
is in agreement with the observed increase in Foxp3 mRNA expression among FACS 
purified CD4
+
 T cells. Likewise, it has been shown that treatment of rheumatoid arthritis 
patients and mice with collagen-induced arthritis with hAM-isolated cells leads to the 
induction of CD4
+
CD25
+
Foxp3
+
 Treg cells, with the ability to suppress T cell responses, 
along with an increased IL-10 production and reduction of Th1 (TNFα, IFNγ and IL-2) and 
Th17 (IL-17) cytokines (Parolini et al. 2014). These last effects were reported to be due to 
the production of soluble mediators derived from cyclooxygenase (COX)-1/2 activation 
(Parolini et al. 2014). In support of this hypothesis, prostaglandins have been shown to be 
crucial for the anti-proliferative effects of conditioned medium from hAM cells (Rossi et 
al. 2012). 
He et al. (2008) have demonstrated that hAM extract retains the anti-inflammatory 
properties of hAM and went on to isolate a complex formed between pentraxin 3 and high 
molecular weight hyaluronic acid (HC-HA/PTX3) that was capable of inhibiting T cell 
proliferation, inducing Foxp3
+
 T cells from CD4
+
 T lymphocytes and suppressing CD4
+
 T 
cell polarization into Th1 cells, in vivo (He et al. 2014). Another study, by Tan et al. 
(2015), suggested that hAM epithelial cells-mediated promotion of Treg cell expansion, 
and differentiation of Fox3
-
 T lymphocytes into Foxp3
+
 Treg cells, required TGFβ, and the 
group successfully prevented the promotion of Foxp3 transcripion in naïve CD4
+
 T cells 
by adding anti-TGFβ1 blocking antibodies. The involvement of TGFβ was also reported in 
a study by Liu et al. (2012), wherein hAM epithelial cells suppressed splenocyte 
proliferation, induced by non-specific and antigen-specific stimulation, in a TGFβ and 
PGE2 dependent manner, but seemingly independent of HGF, NO or IL-10, which were 
not present in the hAM epithelial cells conditioned medium. 
hAM-derived MSCs, and their conditioned medium, have also been shown to, like hAM 
cells, downregulate the expression of Th1 and Th17-related markers, decrease the 
production of the pro-inflammatory cytokines TNFα, IFNγ, IL-1β (Th1), IL-5, IL-6 (Th2), 
IL-9 (Th9), IL-17A and IL-22 (Th17-related), and induce Treg cells among CD4
+
 T cells 
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(Pianta et al. 2015). In a a study by Kang et al. (2012), hAM-derived MSCs were able to 
suppress mitogen-activated T cell proliferation, in a dose dependent manner, and also 
diminished IL-17 and IFNγ production while increasing IL-10 production by total T 
lymphocytes. The group demonstrated that these effects were likely linked to IDO, PGE2, 
TGFβ and HGF production by the hAM-derived MSCs. 
An anti-inflammatory effect was also observed among the purified CD8
+
 and γδ T cells. 
In these cell populations, there was a significant decrease in the mRNA expression for the 
cytolytic protein perforin 1, the apoptosis-inducing protein granzyme B, and of the 
activating receptor NKG2D, which suggests that the hAME can suppress activation and 
cytotoxic functions of CD8
+
 and γδ T cells. Among γδ T cells, there was also a reduction in 
the mRNA expression of eomesodermin (EOMES), a key transcription factor of cytotoxic 
lymphocyte lineages which contributes to IFNγ production in γδ T cells (Chen et al. 2007). 
As mentioned, the hAM, especially hAM epithelial cell, expresses soluble HLA-G (Kubo 
et al. 2001), and produce prostaglandins, including PGE2 (Ueta et al. 2002, Rossi et al. 
2012). Likewise, human MSCs are known to also produce both HLA-G5 (Ryan et al. 2005, 
Selmani et al. 2008) and PGE2 (Dhingra et al. 2013, Rasmusson et al. 2005, Zhang et al. 
2013), which are thought to contribute for the promotion of Treg cells generation, 
suppression of inflammatory Th phenotypes and inhibition of cytotoxic cells, including the 
inhibition CD8
+
 T lymphocytes activation and suppression of effector CD8
+
 T cell 
responses (Bahri et al. 2006). Furthermore, Li et al. (2014) reported MSC-mediated 
reduction of cytokine production and NKG2D downregulation in CD8
+
 T cells, resulting in 
CD8
+
 T cells, with diminished NKG2D expression, with impaired proliferation after 
mitogen stimulation. The group managed to partially restore T cell proliferation with a 
combination of PGE2, IDO and TGFβ inhibitors (Li et al. 2014). 
Within sorted Treg cells, hAME did not seem to influence the expression of Foxp3 
mRNA; however, the augmented expression of IL-10 mRNA suggests that the presence of 
hAME stimulated immune regulation by Treg cells. 
MSC-mediated immunosuppression is known to involve different mechanisms, one of 
which being the generation functional Treg cells, both through direct cell contact and 
through the release of soluble factors (Aggarwal & Pittenger 2005, Luz-Crawford et al. 
2013, Pianta et al. 2015, Ren et al. 2008, Tasso et al. 2012), but, whether these suppressor 
T cells come from an increased proliferation of natural Treg and/or from the the induction 
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of Tregs from Th0, Th1 or Th17 cell subsets is still up to debate. In a study by Luz-
Crawford et al. (2013), it was demonstrated that the CD4
+
CD25
+
Foxp3
+
 T cells obtained 
when human PBMC where co-cultured with MSCs had a relatively low expression of 
neuropilin-1 and protein helios (two markers that allow for the distinction between nTreg 
and iTreg cells); a phenotype typical for iTreg cells. The group also verified that, along 
with the Treg generation, IL-10 levels were augmented in the supernatant of the co-culture. 
The identity of the immunosuppressive factors present in hAME is unknown, but the 
aforementioned study, Luz-Crawford and colleagues (2013) identified MSC-derived IL-10, 
PGE2 and TGFβ1 as important players in the Treg conversion. 
hAM epithelial cells share with MSCs this ability to generate functional Treg cells since, 
as mentioned, hAM-derived cells can increase Treg numbers partially through the 
promotion of Treg expansion and partially through the Treg induction from Foxp3
-
 CD4
+
 T 
cells (MacDonald’s et al. 2015, Parolini et al. 2014, Tan et al. 2015). 
In line with the abovementioned observations; CD4
+
 T cells co-cultured with hAME 
showed an increase in Foxp3 and IL-10 expression at the mRNA level, which may be 
indicative of the generation of induced CD4
+
Foxp3
+
 T cells. In addition, while the levels of 
IL-10 mRNA expression where increased by the presence of hAME within the purified 
natural Treg cells, Foxp3 expression seemed to be unaffected, suggesting that the hAME 
increases the regulatory T cell phenotypes by inducing iTreg cells, and not nTreg cells, 
though it was capable of stimulating IL-10 expression by pre-existent nTreg cells.  
Interestingly, in parallel with increased IL-10 expression, there was a marked decrease in 
the mRNA expression of TGFβ1. While TGFβ1 is generally considered an anti-
inflammatory, immunosuppressive cytokine, it also plays a major role in fibrotic response 
by inducing fibroblasts to synthesize extracellular matrix, and thus is a potential target for 
anti-scarring therapies. In fact, the anti-fibrotic activity of hAM in has been reported to 
involve suppression of TGFβ expression (Guo et al. 2011, Lee et al. 2000, Tseng et al. 
1999). Likewise, while both T lymphocytes and MSCs produce TGFβ, co-cultures of the 
two have been shown to result in a suppression of TGFβ by the lymphocytes (Zhou et al. 
2011). Furthermore, Xu and colleagues (2013) demonstrated that adding TGFβ1 to the 
culture medium can directly affect MSCs, reversing their anti-inflammatory effects, instead 
of acting in synergy with MSCs in the suppression of immune responses, as the group had 
initially expected. On the other hand, Pianta et al. (2015) showed that co-culture of 
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alloreactive T lymphocytes with hAM-derived MSC condioned medium (instead of MSC 
cells) resulted in an induction of Treg cells and increased TGFβ production. However, said 
increase only ocurred following three or more days of co-culture and the authors observed 
no change in the TGFβ levels for shorter periods (Pianta et al. 2015). 
Co-culture of PBMC with the isolated hAM-derived cells did not result in the same 
inhibitiory effects observed for the extract. In fact, only IL-2 producing cells were 
significantly affected by the presence of hAM-derived cells, and, even then, statistical 
significance was only observed among the TCM subset, and only for the lowest ratio of 
PBMC to hAM-derived cells (2:1). The results obtained for hAME had shown that IL-2
+
 T 
cells were more strongly inhibited than TNFα+ or IFNγ+ T cells, and TCM cells were also 
very susceptible to inhibition, which could explain why only these cells were affected by 
the presence of hAM-derived cells. 
Even though the doses of hAM added to the cell cultures were relatively low in 
comparison to the number of PBMC (PBMC-to-hAM cell ratios of 10:1 and 2:1) it was 
still expected inhibition of the frequency of pro-inflammatory cytokines producing cells. 
Liu et al. (2012) achieved a dose-dependent inhibition of mitogen-induced lymphocyte 
proliferation with ratios of 1:5 to 1:10240 of hAM epithelial cells-to-mouse splenocytes, 
and, in a study by McDonald and colleagues (2015); hAM epithelial cells suppressed the 
proliferation of T cells, activated with anti-CD3/CD28, at ratio of 25:1 (human PBMC-to-
hAM epithelial cells). 
The lack of inhibitory effect over the frequency of pro-inflammatory cytokine producing 
T lymphocytes observed for hAM-derived cells could be due to the low percentage of the 
MSCs population within the hAM-derived cell samples (1.8% ± 1.3%) and, consequently, 
to a PBMC-to-hAM-derived MSCs ratios of, approximately, 500:1 and 100:1. The hAME, 
on the other hand, consists of an enriched mixture of the factors from hAM-derived MSCs 
(and hAM epithelial cells), thus possibly ‘bypassing’ the need for higher MSCs content. To 
support this hypothesis; in most studies, MSC-mediated immunosuppressive effects only 
become evident at higher MSC concentrations: in a study by Yang et al. (2009), human 
MSCs were only able to inhibit T cell proliferation at a ratio of 20:1, while the 200:1 and 
2000:1 ratios were ineffective. Kang and colleagues (2012) successfully abrogated the 
proliferation of mitogen-activated T cells by co-culturing PBMC and hAM-derived MSCs 
in a ratio of 2:1 and 10:1, but failed to do so with a 100:1 ratio. Likewise, Le Blanc et al. 
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(2003) observed a decrease in T cell proliferation, in a mixed lymphocyte reaction, when 
MSCs were added to the culture medium at a 10:1 ratio (human peripheral blood 
lymphocytes-to-MSCs), but not 100:1. Interestingly, in the same study, allogeneic MSCs 
could also suppress mitogen-induced proliferation (PHA) at a 10:1 ratio, and not 1000:1, 
but the study described a slight decrease in proliferation at the lowest MSC concentration 
when autologous MSCs were used instead, the group concluded that the mechanism of 
inhibition may differ, at least a bit, between the two (Le Blanc et al. 2003). 
Furthermore, Ribeiro et al. (2013) demonstrated that MSCs from umbilical cord matrix, 
adipose tissue and bone marrow suppressed T cell activation, following mitogenic 
stimulus, at a ratio of 10:1 (PBMC-to-MSC), however the strenght of this inhibition varied 
between the three types of MSCs. The group also demonstrated that MSCs from different 
sources exerted their inhibitory effect at different stages of T cell activation, thus the 
suppressive mechanism may also vary according to the tissue from which the MSCs are 
isolated (Ribeiro et al. 2013). 
There are many discrepancies from study to study regarding the dosage, efficiency and 
mechanism of MSC-mediated suppression of T cell responses, not only because MSC 
populations differ slightly depending on the species and tissue of origin, but also because 
different cell population and immune cells from different species are differentially 
modulated, and because the behavior of MSCs is environmentally responsive and, thus, is 
substantially affected by the cell isolation method, specific culture conditions and timing 
(Rasmusson et al. 2005). 
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7. GENERAL CONCLUSIONS AND FUTURE PRESPECTIVES 
 
T cells are pivotal players in immunity, both by producing specific immune reactions to 
combat infection and disease, and by directing and regulating immune responses. Because 
of this, T lymphocytes have a crucial role in inflammatory diseases and autoimmunity. In 
all these processes, the differentiation of T cells into effector and memory cells and the 
polarization of T cells onto the different subsets are crucial, given that the overall T cell 
response depends on the balance between the different T cell subpopulations, each with 
different functions and different cytokine profiles. 
The objective of this study was to characterize the effect of hAME over T-cell responses 
of naïve, central memory, effector memory and effector CD4
+
 and CD8
+
 T cells. The 
observed effects suggest that the hAME contains bioactive molecules with 
immunosuppressive effects. The presence of hAME in culture suppressed mitogen-
activated cell proliferation and reduced the frequency of pro-inflammatory cytokine 
producing CD4
+
 and CD8
+
 T cells, but to a different extent depending on the subset and 
cytokine under study. Overall the TCM subset seems to be the most susceptible to inhibition 
among both CD4
+
 and CD8
+
 T cells. Additionally; IL-2
+
 T cells appear to be more readily 
inhibited by hAME than TNFα+ or IFNγ+ T cells.  
The apparent decrease in the frequency of CD4
+
 T cells that produce cytokines type 1 
(TNFα, IFNγ and IL-2), Th17-related (IL-17) and Th9-related (IL-9), along with the 
reduction in IL-4 (a type 2 cytokine), GATA3 and STAT6 (Th2-associated transcription 
factors) mRNA expression and upregulation of Foxp3 and IL-10, suggests that hAME 
causes a skewing of CD4
+
 T cell polarization towards regulatory phenotypes, along with 
the downregulation of the other T helper subsets. 
Furthermore, the frequency of pro-inflammatory cytokine producing CD8
+
 T cells was 
equally reduced. The hAME also appears hamper the activation and reduce the cytolytic 
activities of CD8
+
 and γδ T cells, since it caused a decrease in the mRNA expression of the 
cytolytic protein perforin 1, the apoptosis-inducing protein granzime B and the activating 
receptor NKG2D among these cell populations. It may also, possibly hamper IFNγ 
production by γδ T cells, through the downregulation of eomesodermin. 
Finally, the increased Foxp3 expression in purified CD4
+
 T cells, but not in purified Treg 
cells, indicates that hAME promotes the generation of iTreg cells. Thus, hAME may 
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mediate immunosuppression by expanding and sustaining a functional peripheral Treg cell 
pool through iTreg cell conversion, along with the induction of IL-10 production (in both 
iTreg and nTreg cells). 
Collectively, these results suggest that hAME could be successfully applied in the 
reduction of inflammatory processes, perhaps providing a convenient cell-free therapy for 
the treatment of immune disorders. However, hAME differentially regulates different 
CD4
+
 and CD8
+
 T cell subsets, thus, additional controlled studies are needed to determine 
the impact of this differential regulation over the therapeutic effect of hAME and to 
confirm effectiveness and safety. 
Finally, because the observed anti-inflammatory properties of hAME are not associated 
with any external stimuli prior to hAME preparation, these properties are intrinsic to the 
hAM, which, in turn, constitutes an attractive source of immunosuppressive factors without 
necessity of complex cell preparation procedures. Future works are required to identify the 
immune modulatory molecules present in hAME. 
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